SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
-------------
SCHEDULE 13-D
Under the Securities Exchange Act of 1934
TATONKA ENERGY, INC.
(Name of Issuer)
COMMON STOCK, $.001 PAR VALUE
(Title of Class of Securities)
835758103
(CUSIP Number)
George C. Barker.
9603 White Rock Trail, Suite 100
Dallas, Texas 75238
(214) 340-9912
(Name, Address and Telephone Number of Person Authorized to Receive Notices and
Communications)
(April 3, 1998)
(Date of Event which Requires the Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to
report the acquisition which is the subject of this Schedule 13D, and is filing
this schedule because of Rule 13d-1(b)(3) or (4), check the following box [_].
NOTE: Six copies of this statement, including all exhibits, should be filed
with the Commission. See Rule 13d-1(a) for other parties to whom copies are to
be sent.
<PAGE>
SCHEDULE 13-D
CUSIP NO. 835758103
1 Names of Reporting Persons. S.S. or I.R.S. Identification Nos. of Above
Persons
GEORGE C. BARKER SS. No. 254660611
2 Check the Appropriate Box if a Member of a Group (a) [_] (b) [_]
3 SEC Use Only
4 Source of Funds SC
5 Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d)
or 2(e) [_]
6 Citizenship or Place of Organization
USA
Number of Shares Beneficially Owned by Each Reporting Person With
7 SOLE VOTING POWER
31,315,245
8 SHARED VOTING POWER
8,768,268
9 SOLE DISPOSITIVE POWER
31,315,245
10 SHARED DISPOSITIVE POWER
8,768,268
11 Aggregate Amount Beneficially Owned by Each Reporting Person
40,083,513
12 Check if the Aggregate Amount in Row (11) Excludes Certain Shares
[-]
<PAGE>
13 Percent of Class Represented by Amount in Row (11)
80.167%
14 Type of Reporting Person
IN
<PAGE>
Item 1. Security and Issuer.
The title and class of equity securities to which this statement relates is
the Common Stock, $.001 par value (the "Company Common Stock"), of Tatonka
Energy, Inc., an Oklahoma corporation,(the "Registrant"). The Registrant's
principal executive offices are located at 9603 White Rock Trail, Suite 100
Dallas, Texas 75238.
Item 2. Identity and Background.
(a) - (f) This statement is being filed by George C. Barker, a United
States citizen who is a resident of Dallas, Texas, and whose business address is
9603 White Rock Trail, Suite 100, Dallas, Texas 75238. This statement is being
filed by Mr. Barker in his individual capacity and as Trustee of the Phy.Med.,
Inc. Employee Stock Ownership Trust.
The present principal occupation or employment of George C. Barker is
serving as the Chief Executive Officer of a company engaged directly and
indirectly in the business of owning and operating a center that provides
medical diagnostic imaging services to physicians in the greater Dallas area and
also managing an imaging center in Plano, Texas, for other owners. The centers
provide a full scope of medical diagnostic imaging services including magnetic
resonance imaging (MRI), computer axial tomography (CAT) scans, x-rays and other
radiological services to physicians.
The name and address of the corporation with which such employment has been
conducted since April 3, 1998, is Tatonka Energy, Inc. 9603 White Rock Trail,
Suite 100, Dallas, Texas 75238. Prior to such date, such employment was
conducted with Phy.Med., Inc. at such address. On such date, Phy.Med., Inc.
changed its name to PhyMed Diagnostic Imaging Center Dallas, Inc. and became an
80% owned subsidiary of Tatonka Energy, Inc. The principal business of PhyMed
Diagnostic Imaging Center Dallas, Inc. (formerly known as Phy.Med., Inc.) is,
and the principal business of Tatonka Energy, Inc. since such date has been, the
operation and management of medical diagnostic imaging centers.
During the last five years George C. Barker has not been convicted in a
criminal proceeding (excluding traffic violations or similar misdemeanors). In
addition, during the last five years, George C. Barker has not been a party to a
civil proceeding of a judicial or administrative body of competent jurisdiction.
Item 3. Source and Amount of Funds or Other Consideration.
See Item 5 below.
Item 4. Purpose of Transaction.
(a)-(j)
1
<PAGE>
The Acquisition:
Mr. Barker made the acquisition described in Item 5 below to acquire a
controlling equity interest in the Registrant and to take control of the
management and direction of the Registrant, including the changes in management
and the contemplated changes in business described below.
Present and Proposed Changes in Management:
The Directors of the Registrant at the time of the merger were Messrs. Joe
Love and Joe Foor, who are continuing as Directors. In addition, at the time of
the merger, George C. Barker was elected to the Board of Directors of the
Registrant to fill a vacancy which existed on the Board of Directors.
At the next annual meeting of stockholders to be held in May 1998, (or
consents in lieu of such a meeting), Messrs. Barker, Love and Foor will be
re-elected for the coming year and two additional Directors will be elected:
Marilyn Moss and Judith F. Barker. George C. Barker and Judith F. Barker are
married.
In addition, at the time of the merger, George C. Barker was also elected
Chairman of the Board, President and Chief Executive Officer, and Judith F.
Barker was elected Secretary and Treasurer of the Registrant. Joe Foor and Joe
Love resigned as President and Secretary of the Registrant so that Mr. and Mrs.
Barker could be elected to their present positions. In addition, Marilyn Moss
was elected Executive Vice President - Operations.
At the annual meeting of the Board of Directors to be held following the
annual meeting of stockholders (or consents in lieu of such meeting), the
following officers will be re-elected for the coming year:
George C. Barker Chairman of the Board, President
and Chief Executive Officer
Marilyn Moss Executive Vice President - Operations
Judith F. Barker Secretary and Treasurer
The corporate offices of the Registrant have been moved to the offices of
PhyMed and are now located at 9603 White Rock Trail, Suite 100, Dallas, Texas
75238.
Contemplated Changes in PhyMed's and the Registrant's Business:
PhyMed is a seven-year-old company engaged in the operation and management
of medical diagnostic imaging centers, which provide a full scope of medical
diagnostic imaging services including magnetic resonance imaging (MRI), computer
axial tomography (CAT) scans, x-rays and
2
<PAGE>
other radiological services to physicians.
Prior to the acquisition, PhyMed was a privately-held company and the
transaction with PhyMed was undertaken as part of an overall plan for expanding
the business of PhyMed through, among other possible endeavors, the development
of new centers, acquisitions of existing centers and exclusive capitated
services contracts, with a view towards increasing the per-share value of the
Registrant for the benefit of the shareholders.
This expansion will require additional capital, and the managements of the
Registrant and PhyMed believe that raising additional capital can best be
achieved through PhyMed having access to the public shareholders and reporting
company status under the Securities Exchange Act of 1934, which the Registrant
affords. The principle followed in determining the amount of consideration to be
exchanged by the Registrant for PhyMed was the percentage of the equity of
PhyMed the owners of PhyMed would cede in order to gain such access and have the
opportunity to raise such capital.
In furtherance of this goal of raising additional capital for expansion,
the Registrant has recently commenced a private offering of securities to
accredited investors only. The offering seeks to raise a minimum of $200,000 and
a maximum of $3,000,000 from the sale of Units of a new series of Preferred
Stock and Warrants to purchase Common Stock.
Operation of Outpatient Radiological Diagnostic Centers. Currently, PhyMed
owns and operates a diagnostic imaging center in Dallas, Texas. The Center
provides diagnostic services to physicians in the greater Dallas area. It also
manages an imaging center in Plano, Texas for other owners. The Center is
located at 9603 White Rock Trail, Suite 100 in Dallas. The Center's services
include magnetic resonance imaging (MRI), computerized axial tomography (CAT),
fluoroscopy, radiology, invasive procedures, pain management, ultrasound and
mammography. The Center is well known for its quality of service to patients and
referring physicians.
The Registrant has plans to expand PhyMed's operations in the Dallas/Fort
Worth market and other targeted markets in the immediate future. Discussions are
being held with other parties on the acquisition of existing centers. Locations
for new centers have been identified and negotiations on leases have begun.
Capitated Radiological Services. PhyMed has recently completed a letter of
agreement with a national firm. Under the agreement, PhyMed will provide
radiological technical services on a capitated basis to approximately 40
physician offices in Texas. PhyMed will provide these services on an exclusive
basis.
A second agreement is being negotiated with another large independent
physician's (IPA) association in the Dallas market. Under this agreement, PhyMed
will provide all of the IPA's radiological services on an exclusive basis. This
agreement will also have a capitated element as well as a traditional payment
element.
3
<PAGE>
Proposals for capitated agreements are being prepared for large payors in
the Dallas marketplace. These proposals, if successful, would make PhyMed's
centers the exclusive provider of radiological services for the payor's
subscribers in the targeted markets.
Radiological Professional Practices. PhyMed has relationships with
physicians specializing in radiology and is developing a management practice
division to provide these specialized services to its own Centers as well as to
other providers such as hospitals and clinics. The long-range plan is that this
division would become a nationwide provider of professional radiological
services.
Capitated Services Division. PhyMed has recently established a Capitated
Services Division to market its radiological services to self-insured
corporations, health maintenance organizations, preferred provider organizations
and insurance companies. Under the Capitated Services program, PhyMed will
provide radiological services under a exclusive risk-based system of
reimbursement. The payor the will pay PhyMed a negotiated rate for each member
per month. The aim of the Capitated Services program is to provide the purchaser
a known expense per month for the services and PhyMed receives payments on a
regular basis. Working with the payor, PhyMed will develop utilization
management programs to help manage the utilization of radiological services by
the members.
PhyMed intends to commence negotiations with one or more insurance
companies to offer its Capitated Services program by the beginning of the second
quarter 1998.
Professional Management Services Division. PhyMed has plans to develop a
physician practice management and services division. This division will
concentrate in the radiologist specialty area. Management of PhyMed has
considerable experience in this area of medicine and as a medical imaging
company can offer radiologists opportunities to expand their practices and at
the same time increase the net revenues of PhyMed.
See Items 5 and 6 below.
Item 5. Interest in Securities of the Issuer.
(a)-(e) On April 3, 1998, George C. Barker, ("Barker"), individually and as
Trustee for the Phy.Med., Inc. Employee Stock Ownership Plan (the "ESOP"),
acquired control of the Registrant. Prior to such date, such parties owned all
the outstanding shares of Phy.Med., Inc., a Texas corporation ("PhyMed"), and on
such date they acquired from the Registrant, in the aggregate, immediate
ownership of and the right to receive an aggregate of 69,415,409 authorized but
unissued shares of Common Stock, $.001 par value, of the Registrant, as
presently constituted, which, if all such shares were outstanding, would
constitute 88.5% of the Registrant's presently outstanding 78,430,965 shares of
Common Stock (87.5% of the 79,331,896 shares which would be outstanding on a
fully diluted basis).
The terms of the acquisition contemplate a 1-for-10 reverse stock split
which will become
4
<PAGE>
effective after compliance with all necessary corporate and regulatory
formalities (presently estimated to be in May 1998). Upon the effectiveness of
such reverse split, Barker and the ESOP will own 6,941,541 shares of 7,843,097
shares, $.01 par value, outstanding (7,933,190 shares on a full diluted basis).
(The Registrant will continue to have 50,000,000 shares of Common Stock
authorized.)
Barker is the sole trustee of the ESOP and as such has the power to vote
the shares owned by the ESOP on matters such as the uncontested election of
Directors. Barker and his wife, Judith F. Barker, own in the aggregate
approximately 70% of the vested interests of the participants in the ESOP.
On March 6, 1998, certain parties entered into an Agreement and Plan of
Reorganization and Merger (the "Agreement"). The parties were Barker and the
ESOP, in their capacity as the shareholders of PhyMed, PhyMed itself, the
Registrant and Tatonka Subsidiary, Inc., a newly-formed and wholly-owned
subsidiary of the Registrant. The Agreement was consummated on April 3, 1998, by
means of a statutory merger of Tatonka Subsidiary, Inc. into PhyMed, with PhyMed
being the surviving corporation. As a result of the merger, PhyMed is now an 80%
owned subsidiary of the Registrant, and the ESOP owns the remaining 20% of
PhyMed.
Prior to the merger, there were 800 common shares of PhyMed outstanding, of
which 500 were owned by Barker, individually, and 300 were owned by the ESOP.
In the merger, the 500 PhyMed common shares owned by Barker were converted
into immediate ownership of and the right to receive 54,230,788 shares of Common
Stock of the Registrant, and 140 of the 300 PhyMed common shares owned by the
ESOP were converted in like manner into 15,184,621 shares of Common Stock of the
Registrant. The remaining 160 PhyMed common shares held by the ESOP now
constitute the 20% of PhyMed common shares not owned by the Registrant.
The Registrant has 50,000,000 shares of Common Stock authorized for
issuance and, at the time of the merger, had 9,916,487 shares issued and
outstanding or reserved for issuance. To the extent that the terms of the merger
would have resulted in the issuance of more than 50,000,000 shares, the excess
over 50,000,000 shall not be issued until such time as the stockholders of the
Registrant have approved an appropriate amendment to the Registrant's
Certificate of Incorporation. Prior to such approval, Barker and the ESOP will
continue to have a contractual right, pursuant to the Agreement and the Articles
of Merger filed with the Secretary of State of Texas at the time of the merger,
to receive such excess shares, subject to such required stockholder approval.
In summary, Barker and the ESOP received an aggregate of 40,083,513 shares
of the Registrant at the time of the merger, the same being 80.167% of the
50,000,000 and outstanding shares on a fully-diluted basis. Of such number,
Barker, individually, received 31,315,245 shares (approximately 62.6%) of the
outstanding shares, and the ESOP received 8,768,268 shares (approximately
17.5%), both percentages on a fully-diluted basis.
5
<PAGE>
Barker and the ESOP continue to have a contractual right to receive, in the
aggregate, an additional 29,331,896 shares, which will result in their having,
collectively, 87.5% of the Common Stock of the Registrant on a fully-diluted
basis. Of such additional shares, 22,915,544 will be received by Barker,
individually, and 6,416,352 shares will be received by the ESOP.
The parties to the Agreement contemplate that the Board of Directors and
stockholders of the Registrant will approve an amendment to the Registrant's
Certificate of Incorporation approving a 1-for-10 reverse stock split (including
an increase in the par value of the Common Stock from $.001 to $.01) and a
change of the Registrant's name to "PhyMed, Inc.". Upon the effectiveness of
such reverse stock split, all outstanding shares of common stock of the
Registrant, including the shares which were issued to Barker and the ESOP upon
the effectiveness of the merger, will represent one-tenth (1/10th) as many
shares. In addition, all shares reserved for issuance, including the shares
which the Registrant will still have a contractual obligation to issue to Barker
and the ESOP, will become rights to receive one-tenth (1/10th) as many shares.
The unissued shares due Barker and the ESOP from the merger will then be
immediately issued because the Registrant will then have a sufficient number of
authorized but unissued shares to issue for this purpose.
Possible Change of Control
The 800 shares of PhyMed owned by Barker and the ESOP at the time of the
merger were pledged to Patrick Alan Luckett ("Luckett") to secure the payment of
(a) two promissory notes payable to the order of Luckett, which were issued to
him as partial payment for shares of PhyMed purchased from him, and (b) a
guaranty of such notes.
On September 21, 1993, Barker and Luckett owned all the then outstanding
common shares of PhyMed, Inc., each of them owning of 500 common shares. On such
date Luckett sold 200 of his shares to PhyMed and 300 shares to the ESOP. The
sales were for cash and promissory notes. One note was issued by PhyMed in the
original principal amount of $800,000 pursuant to the terms of a Loan and
Security Agreement dated September 21, 1993, and the second promissory note was
issued by the ESOP in the original principal amount of $800,000. Both notes were
guaranteed by Barker. The PhyMed note was secured by the 200 shares repurchased
from Luckett by PhyMed; the ESOP note was secured by the 300 shares the ESOP
purchased from Luckett; and the 500 shares already owned by Barker were pledged
to secure his guaranty of the two notes.
The aggregate of 69,415,409 shares of Common Stock of the Registrant
received and to be received by Barker and the ESOP as a result of the merger
have been and will be substituted in the pledge for the 640 PhyMed shares which
were released from the pledge and converted into such shares of Common Stock of
the Registrant. The 20% of PhyMed still owned by the ESOP remains pledged for
such purpose.
As of April 1, 1998, the unpaid principal balance on the PhyMed note was
$186,008, and the ESOP note was $384,167.
6
<PAGE>
Except as set forth in this Schedule 13D, including Item 6 below, there
have been no transactions by Barker or the ESOP in the Common Stock of the
Registrant within the last 60 days.
See Item 6 below.
Item 6. Contracts, Arrangements, Understandings or Relationships With
Respect to Securities of the Issuer.
See Item 5 above.
The Board of Directors of the Registrant has agreed informally to grant Mr.
Barker an option to purchase 500,000 shares of Common Stock with vesting to be
contingent upon the attainment by the Company of certain financial objectives.
The Board of Directors has also agreed informally to grant each Mr. Love and Mr.
Foor an option to purchase 250,000 shares of Common Stock. The terms of such
options have not yet been determined by the Board of Directors.
Except as set forth in this Schedule 13D, there are no presently existing
contracts or other agreements between Barker and any other person regarding the
securities of the Registrant.
Item 7. Material to Be Filed as Exhibits
Attached as Exhibits are the following documents:
Exhibit Number Description
-------------- -----------
1. Agreement and Plan of Reorganization and Merger dated as of March
6, 1998 by and among Tatonka Energy, Inc. Tatonka Energy
Subsidiary, Inc. Phy. Med., Inc. and the Stockholders of PhyMed,
Inc.
7
<PAGE>
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
Date: April 10, 1998 /s/ George C. Barker
--------------------
George C. Barker
8
<PAGE>
EXHIBIT 1 TO SCHEDULE 13D
AGREEMENT AND PLAN OF REORGANIZATION AND MERGER
dated as of
March 6, 1998
by and among
TATONKA ENERGY, INC.
(an Oklahoma corporation);
TATONKA ENERGY SUBSIDIARY, INC.
(a Texas corporation),
PHY. MED., INC.
(a Texas corporation)
and
THE STOCKHOLDERS OF PHYMED, INC.
9
<PAGE>
<TABLE>
TABLE OF CONTENTS
<S> <C> <C>
Page
ARTICLE I DEFINITIONS...................................................................................2
Section 1.1 Definitions.......................................................................2
Section 1.2 Rules Of Interpretation...........................................................5
ARTICLE II THE MERGER...................................................................................5
Section 2.1 The Merger........................................................................5
Section 2.2 The Closing.......................................................................6
Section 2.3 Effective Time....................................................................6
Section 2.4 Articles of Incorporation of Surviving Corporation................................6
Section 2.5 Bylaws of Surviving Corporation...................................................6
Section 2.6 Directors of the Surviving Corporation............................................6
Section 2.7 Officers of the Surviving Corporation.............................................6
Section 2.8 Conversion of Company Common Stock................................................6
Section 2.9 Exchange of Certificates Representing Shares of the Company
Common Stock...........................................................................8
Section 2.10 Fractional Shares................................................................8
Section 2.11 Percentage Protection Provision....................................................8
ARTICLE III REPRESENTATIONS AND WARRANTIES OF THE COMPANY...............................................9
Section 3.1 Organization and Good Standing; Qualification.....................................9
Section 3.2 Authorization and Validity.......................................................10
Section 3.3 Governmental Authorization.......................................................10
Section 3.4 Capitalization...................................................................10
Section 3.5 Transactions in Capital Stock....................................................11
Section 3.6 Continuity of Business Enterprise................................................11
Section 3.7 Subsidiaries and Investments.....................................................11
Section 3.8 Absence of Conflicting Agreements or Required Consents...........................11
Section 3.9 Absence of Changes...............................................................12
Section 3.10 No Undisclosed Liabilities.......................................................13
Section 3.11 Litigation and Claims............................................................13
Section 3.12 No Violation of Law..............................................................13
Section 3.13 Lease Agreements.................................................................13
Section 3.14 Real and Personal Property.......................................................14
Section 3.15 Indebtedness for Borrowed Money..................................................14
Section 3.16 Contracts and Commitments........................................................14
Section 3.17 Employee Matters.................................................................15
Section 3.18 Labor Relations..................................................................16
Section 3.19 Employee Benefit Plans...........................................................16
Section 3.20 Environmental Matters............................................................18
Section 3.21 Filing Reports...................................................................19
Section 3.22 Insurance Policies...............................................................19
Section 3.23 Licenses, Authorization and Provider Programs....................................20
10
<PAGE>
Section 3.24 Inspections and Investigations...................................................21
Section 3.25 Proprietary Rights and Information...............................................22
Section 3.26 Taxes............................................................................22
Section 3.27 Related Party Arrangements.......................................................24
Section 3.28 Banking Relations................................................................24
Section 3.29 Fraud and Abuse and Self Referral................................................24
Section 3.30 Restrictions on Business Activities..............................................24
Section 3.31 Agreements in Full Force and Effect..............................................24
Section 3.32 Statements True and Correct......................................................25
Section 3.33 Disclosure Schedules.............................................................25
Section 3.34 Finders' Fees....................................................................25
ARTICLE IV REPRESENTATIONS AND WARRANTIES OF TATONKA....................................................25
Section 4.1 Organization and Good Standing; Qualification....................................25
Section 4.2 Authorization and Validity.......................................................26
Section 4.3 Governmental Authorization.......................................................26
Section 4.4 Capitalization...................................................................26
Section 4.5 Absence of Conflicting Agreements or Required Consents...........................27
Section 4.6 Absence of Changes...............................................................28
Section 4.7 No Undisclosed Liabilities.......................................................28
Section 4.8 Litigation and Claims............................................................28
Section 4.9 No Violation of Law..............................................................28
Section 4.10 Employee Matters.................................................................28
Section 4.11 Taxes............................................................................28
Section 4.12 Related Party Arrangements.......................................................30
Section 4.13 Statements True and Correct......................................................30
Section 4.14 Disclosure Schedules.............................................................30
Section 4.15 Finder's Fees....................................................................30
ARTICLE V CLOSING DATE REPRESENTATIONS AND WARRANTIES REGARDING
TATONKA SUB.............................................................................30
Section 5.1 Authorization and Validity.......................................................30
Section 5.2 No Violation.....................................................................30
Section 5.3 No Business, Agreements, Assets or Liabilities ..................................30
ARTICLE VI COVENANTS OF THE COMPANY.....................................................................31
Section 6.1 Conduct of The Company...........................................................31
Section 6.2 Title to Assets; Indebtedness....................................................32
Section 6.3 Access...........................................................................32
Section 6.4 Acquisition Proposals............................................................33
Section 6.5 Compliance With Obligations......................................................33
Section 6.6 Notice of Certain Events.........................................................33
Section 6.7 Stockholders' Consent............................................................34
Section 6.8 Obligations of Company and Stockholders..........................................34
Section 6.9 Accounting and Tax Matters........................................................34
11
<PAGE>
ARTICLE VII COVENANTS OF TATONKA.......................................................................35
Section 7.1 Consummation of Agreement........................................................35
Section 7.2 Requirements to Effect the Merger and Acquisitions...............................35
Section 7.3 Access...........................................................................35
Section 7.4 Notification of Certain Matters..................................................35
ARTICLE VIII COVENANTS OF TATONKA AND THE COMPANY......................................................35
Section 8.1 Filings; Other Action............................................................35
Section 8.2 Amendments of Disclosure Schedules...............................................36
Section 8.3 Actions Contrary to Stated Intent................................................36
Section 8.4 Public Announcements.............................................................37
Section 8.5 Expenses.........................................................................37
Section 8.6 Patient Confidentiality..........................................................37
Section 8.7 1934 Act filings.................................................................37
ARTICLE IX CONDITIONS PRECEDENT OF TATONKA AND TATONKA SUB.............................................37
Section 9.1 Representations and Warranties....................................................37
Section 9.2 Covenants.........................................................................37
Section 9.3 Proceedings.......................................................................37
Section 9.4 No Material Adverse Effect........................................................38
Section 9.5 Government Approvals and Required Consents........................................38
Section 9.6 Closing Deliveries................................................................38
Section 9.7 Stockholder Representation Letter.................................................38
ARTICLE X CONDITIONS PRECEDENT OF THE COMPANY..........................................................38
Section 10.1 Representations and Warranties...................................................38
Section 10.2 Covenants........................................................................38
Section 10.3 Proceedings......................................................................38
Section 10.4 Government Approvals and Required Consents.......................................38
Section 10.5 Closing Deliveries...............................................................38
Section 10.6 No Material Adverse Effect.......................................................38
ARTICLE XI CLOSING DELIVERIES..........................................................................39
Section 11.1 Deliveries of the Company........................................................39
Section 11.2 Deliveries of Tatonka............................................................40
ARTICLE XII POST CLOSING MATTERS.......................................................................41
Section 12.1 Further Instruments of Transfer..................................................41
Section 12.2 Merger Tax Covenant..............................................................41
Section 12.3 Current Public Information.......................................................41
Section 12.4 Change of Tatonka Name...........................................................41
ARTICLE XIII REMEDIES..................................................................................42
Section 13.1 Indemnification by the Company and the Stockholders..............................42
Section 13.2 Indemnification by Tatonka.......................................................42
Section 13.3 Conditions of Indemnification....................................................43
Section 13.4 Costs, Expenses and Legal Fees...................................................46
Section 13.5 Tax Benefits; Insurance Proceeds.................................................46
Section 13.6 Dispute Resolution...............................................................46
12
<PAGE>
ARTICLE XIV TERMINATION................................................................................48
Section 14.1 Termination......................................................................48
Section 14.2 Effect of Termination............................................................48
ARTICLE XV NONDISCLOSURE OF CONFIDENTIAL INFORMATION...................................................49
Section 15.1 Non-Disclosure Covenant..........................................................49
Section 15.2 Damages..........................................................................50
Section 15.3 Survival.........................................................................50
ARTICLE XVI MISCELLANEOUS..............................................................................50
Section 16.1 Amendment; Waivers...............................................................50
Section 16.2 Assignment.......................................................................50
Section 16.3 Parties in Interest; No Third Party Beneficiaries................................50
Section 16.4 Entire Agreement.................................................................50
Section 16.5 Severability.....................................................................50
Section 16.6 Survival of Representations, Warranties and Covenants............................51
Section 16.7 Governing Law....................................................................51
Section 16.8 Captions.........................................................................51
Section 16.9 Gender and Number................................................................51
Section 16.10 Confidentiality; Publicity and Disclosures.......................................51
Section 16.11 Notice...........................................................................52
Section 16.12 No Waiver; Remedies..............................................................53
Section 16.13 Counterparts.....................................................................53
Section 16.14 Defined Terms....................................................................53
EXHIBITS
Exhibit A - Merger Consideration.......................................................................A-1
Exhibit B - Tatonka Energy, Inc. Preferred Stock Listing...............................................B-1
Exhibit C - Stockholder Representation Letter..........................................................C-1
</TABLE>
13
<PAGE>
AGREEMENT AND PLAN OF REORGANIZATION AND MERGER
This Agreement and Plan of Merger (this "Agreement"), dated as of March 6,
1998, is by and among TATONKA ENERGY, INC., an Oklahoma corporation ("Tatonka"),
TATONKA ENERGY SUBSIDIARY, INC., a Texas corporation and a wholly-owned
subsidiary of Tatonka ("Tatonka Sub"), PHY. MED., INC., a Texas corporation (the
"Company") and GEORGE C. BARKER, a Texas resident ("Barker") and the EMPLOYEE
STOCK OWNERSHIP PLAN OF PHY. MED., INC. (the "ESOP")(Barker and the ESOP are
collectively the "Stockholders").
Recitals
A. The Company is engaged in the business of owning, operating and
acquiring the assets of, and managing the non-medical aspects of, radiology
practices and diagnostic imaging centers. All of the shares of the common stock
of the Company (the "Company Common Stock") are owned beneficially and of record
by the Stockholders.
B. Tatonka is a publicly-held company that desires to acquire the
operations of the Company.
C. Pursuant to this Agreement, Tatonka, Tatonka Sub, and the Company intend
that Tatonka Sub be merged with and into the Company, and that the Company be
the sole surviving corporation (sometimes called the "Surviving Corporation"),
and Tatonka Sub be the disappearing corporation (sometimes called the
"Disappearing Corporation").
D. Tatonka, Tatonka Sub and the Company have each determined to engage in
the transactions contemplated hereby, pursuant to which (i) Tatonka Sub will
merge with and into the Company upon the terms and conditions set forth in this
Agreement and in accordance with the laws of the State of Texas, (ii) 80% of the
outstanding shares of the Company Common Stock shall be converted at such time
into shares of common stock, par value $.001 per share, of Tatonka (the "Tatonka
Common Stock") as set forth in this Agreement, and (iii) the Company shall
become an 80% owned subsidiary of Tatonka.
E. The parties intend for the transaction contemplated by this Agreement to
qualify as a statutory merger within the meaning of Section 368 of the Internal
Revenue Code of 1986, as amended (the "Code") and the regulations promulgated
thereunder.
F. Tatonka has 50,000,000 shares of Common Stock authorized for issuance
and 9,916,487 shares issued and outstanding or reserved for issuance. Issuance
at the effective Time of all the shares representing the Merger Consideration
would result in the issuance of more than such 50,000,000 authorized shares.
G. The parties to this Agreement contemplate that the Board of Directors
and stockholders of Tatonka will approve an amendment to Tatonka's Certificate
of Incorporation approving a 1-for-10 reverse stock split.
1
<PAGE>
H. Upon the effectiveness of such reverse stock split, the shares which
have been issued to the Stockholders at the Effective Time will represent
one-tenth (1/10th) as many shares as when issued at the Effective Time, and the
unissued number of shares which Tatonka will still have a contractual obligation
to issue will also thereafter become one-tenth (1/10th) as many shares and will
be immediately issued because Tatonka will then have a sufficient number of
authorized but unissued shares to issue for this purpose.
Terms and Conditions
NOW, THEREFORE, in consideration of the preceding recitals and the mutual
representations, warranties, covenants and agreements set forth in this
Agreement, the parties agree as follows:
ARTICLE I
DEFINITIONS
Section 1.1. Definitions. As used in this Agreement, the following terms
shall have the meanings set forth below:
"Affiliate" with respect to any person shall mean a person that, directly
or indirectly through one or more intermediaries, controls, is controlled by, or
is under common control with, such person.
"Agreement" shall have the meaning set forth in the preamble to this
Agreement.
"Best knowledge" or "to the knowledge of" and similar phrases shall mean
(i) in the case of a natural person, the particular fact was known, or not
known, as the context requires, to such person after reasonable investigation
and inquiry by such person, and (ii) in the case of an entity, the particular
fact was known, or not known, as the context requires, to any of the
Stockholders, director or executive officer of such entity after reasonable
investigation and inquiry by the executive officers of such entity; provided,
however, that to the extent any of the representations, warranties and
statements of the Company made specifically in Section 3.20 is expressly
qualified to the knowledge or best knowledge of the Company, it shall mean the
knowledge of any of the Stockholders, director or executive officer of the
Company actually possesses without the necessity of any special inquiry as to
the matters which are the subject thereof.
"Claim Notice" shall have the meaning set forth in Section 13.3(a).
"Closing" shall mean the closing of the transactions contemplated by this
Agreement as set forth in Section 2.2.
"Closing Date" shall have the meaning set forth in Section 2.2.
"Code" shall have the meaning set forth in the recitals to this Agreement.
"Company" shall have the meaning set forth in the preamble to this
Agreement.
"Company Common Stock" shall have the meaning set forth in the recitals to
this Agreement.
2
<PAGE>
"Company Balance Sheet" shall mean the unaudited consolidated balance sheet
of Company and its Subsidiaries as of December 31, 1997.
"Company Financial Statements" shall mean the Company Balance Sheet and the
related statements of operations and cash flows of Company and the Company
Subsidiaries for the three months and twelve months then ended.
"Company Right" shall mean all arrangements, calls, commitments,
agreements, options, rights to subscribe to, scrips, understandings, warrants,
or other binding obligations of any character whatsoever relating to or
securities or rights convertible into or exchangeable for, shares of Company
Common Stock, or by which the Company is or may be bound to issue additional
shares of Company Common Stock or other Company Rights.
"Company Subsidiaries" shall have the meaning set forth in Section 3.7.
"Confidential Information" shall mean all trade secrets and other
confidential and/or proprietary information of the particular person, including,
but not limited to, information derived from reports, processes, data, know-how,
software programs, improvements, inventions, strategies, compensation
structures, reports, investigations, research, work in progress, codes,
marketing and sales programs and plans, financial projections, cost summaries,
formulae, contract analyses, financial information, forecasts, confidential
filings with any state or Federal agency, and all other confidential concepts,
methods of doing business, ideas, materials or information prepared or performed
for, by or on behalf of such person by its employees, officers, directors,
agents, representatives, or consultants.
"Damages" shall have the meaning set forth in Section 13.1.
"Disappearing Corporation" shall have the meaning set forth in the recitals
to this Agreement.
"Disclosure Schedules" shall mean the schedules attached to this Agreement
as of this date or otherwise delivered by any party pursuant to the terms of
this Agreement, as amended or supplemented.
"Effective Time" shall have the meaning set forth in Section 2.3.
"Election Period" shall have the meaning set forth in Section 13.3(a).
"Encumbrance" shall mean any charge, claim, community property interest,
equitable interest, lien, option, pledge, security interest, right of first
refusal, or restriction of any kind, including any restriction on use, voting,
transfer, receipt of income or exercise of any other attribute of ownership.
"Environmental Laws" shall have the meaning set forth in Section 3.20(e).
"ERISA" shall have the meaning set forth in Section 3.17.
"Exchange Act" shall mean the Securities Exchange Act of 1934, as amended.
"Indemnified Party" shall have the meaning set forth in Section 13.3(a).
"Indemnifying Party" shall have the meaning set forth in Section 13.3(a).
3
<PAGE>
"Indemnity Notice" shall have the meaning set forth in Section 13.3(d).
"Insurance Policies" shall have the meaning set forth in Section 3.22.
"IRS" shall mean the Internal Revenue Service.
"Lease Agreements" shall have the meaning set forth in Section 3.13.
"Material Adverse Effect" shall mean a material adverse effect on the
assets, properties, business, operations, condition (financial or otherwise),
liabilities or results of operations of the Person or Persons being referred to,
taken as a whole (including its consolidated subsidiaries, if any), in
consideration of all relevant facts and circumstances.
"Medical Waste" shall mean (i) pathological waste, (ii) blood, (iii)
sharps, (iv) wastes from surgery or autopsy, (v) dialysis waste, including
contaminated disposable equipment and supplies, (vi) cultures and stocks of
infectious agents and associated biological agents, (vii) contaminated animals,
(viii) isolation wastes, (ix) contaminated equipment, (x) laboratory waste, (xi)
any substance, pollutant, material, or contaminant listed or regulated under any
Medical Waste Law, and (xii) other biological waste and discarded materials
contaminated with or exposed to blood, excretion, or secretions from human
beings or animals.
"Medical Waste Laws" shall mean the following, including regulations
promulgated and orders issued thereunder, as in effect on the date hereof and
the Closing Date: (i) the MWTA, (ii) the U.S. Public Vessel Medical Waste
Anti-Dumping Act of 1988, 33 USCA Sections 2501 et seq., (iii) the Marine
Protection, Research, and Sanctuaries Act of 1972, 33 USCA Sections 1401 et
seq., (iv) The Occupational Safety and Health Act, 29 USCA Sections 651 et seq.,
(v) the United States Department of Health and Human Services, National
Institute for Occupational Safety and Health, Infectious Waste Disposal
Guidelines, Publication No. 88-119, and (vi) any other Federal, state, regional,
county, municipal, or other local laws, regulations, and ordinances insofar as
they are applicable to any of the Company's assets or operations and purport to
regulate Medical Waste or impose requirements related to Medical Waste.
"Merger" shall have the meaning set forth in Section 2.1.
"Merger Consideration" shall have the meaning set forth in Section 2.8(a).
"MWTA" shall mean the Medical Waste Tracking Act of 1988, 42 U.S.C.
Sections 6992, et seq.
"Ordinary course of business" shall mean the usual and customary way in
which the particular entity has conducted its business in the past.
"Payors" shall mean any and all private or governmental Persons, obligated
by contract or by law to render payment to the Company in consideration of the
performance of professional medical or technical services including, but not
limited to, Medicare and Medicaid Programs (as defined in Section 3.23(a)),
insurance companies, health maintenance organizations, preferred provider
organizations, independent practice associations, hospitals, hospital systems,
integrated delivery systems and CHAMPUS.
4
<PAGE>
"Person" shall mean any natural person, corporation, partnership, joint
venture, limited liability company, association, group, organization or other
entity.
"Regulated Activity" shall have the meaning set forth in Section 3.20(c).
"Reorganization" shall have the meaning set forth in Section 12.2.
"SEC" shall mean the Securities and Exchange Commission.
"Securities Act" shall mean the Securities Act of 1933, as amended.
"Stockholders" shall mean the stockholders of the Company immediately prior
to the Effective Time.
"Surviving Corporation" shall have the meaning set forth in the recitals to
this Agreement.
"Tatonka" shall have the meaning set forth in the preamble to this
Agreement.
"Tatonka Common Stock" shall have the meaning set forth in the recitals to
this Agreement.
"Tatonka Current Balance Sheet" shall mean the unaudited consolidated
balance sheet of Tatonka and its Subsidiaries as of September 30, 1997.
"Tatonka Subsidiaries" shall have the meaning set forth in Section 4.5.
"Tax Returns" shall include all Federal, state, local or foreign income,
excise, corporate, franchise, property, sales, use, payroll, withholding,
provider, environmental, duties, value added and other tax returns (including
information returns).
"Third Party Claim" shall have the meaning set forth in Section 13.3(a).
Section 1.2. Rules Of Interpretation. The definitions set forth in Section
1.1 shall be equally applicable to both the singular and the plural forms of the
terms therein defined and shall cover both genders.
Unless otherwise indicated, reference o an Article number (e.g., Article
IV) or a Section number (e.g., Section 6.2) shall be construed to be a reference
to the designated Article number or Section number of this Agreement.
ARTICLE II
THE MERGER
Section 2.1. The Merger. Subject to the terms and conditions of this
Agreement, at the Effective Time, Tatonka Sub shall be merged with and into the
Company in accordance with this Agreement and the separate corporate existence
of the Disappearing Corporation shall thereupon cease (the "Merger"). The
Company shall be the Surviving Corporation in the Merger and shall continue to
be governed by the laws of the State of Texas, and the separate corporate
existence of the Company with all its rights, privileges, powers, immunities,
purposes and franchises shall continue unaffected by the Merger, except as set
forth in this Agreement. The Surviving Corporation may, at any time concurrent
with and/or
5
<PAGE>
after the Effective Time, take any action in the name of or on behalf of the
Disappearing Corporation in order to effectuate the transactions contemplated by
this Agreement.
Section 2.2. The Closing. Unless this Agreement has been terminated in
accordance with its terms, the closing (the "Closing") shall take place at 10:00
a.m., local time, on March 20, 1998, at the offices of McKinnon & Associates,
Inc., a Professional Corporation, 10000 North Central Expressway, Suite 1540,
Dallas, Texas 75231-416, or such other time and/or place as may be mutually
agreed by the parties to this Agreement. If the Closing shall not have taken
place by April 30, 1998, this Agreement shall automatically terminate and shall
be of no further force or effect, unless extended by the mutual agreement of the
parties to this Agreement.
Section 2.3. Effective Time. If all the conditions to the Merger set forth
in Articles IX and X shall have been fulfilled or waived in accordance herewith
and this Agreement shall not have been terminated in accordance with Article
XIV, the parties hereto shall cause to be properly executed and filed on the
Closing Date, Articles of Merger meeting the requirements of Section 5.04 of the
Texas Business Corporation Act. The Merger shall become effective at the time of
the filing of such documents with the Secretary of State of the State of Texas,
in accordance with such law or at such later time which the parties have agreed
upon and designated in such filings as the effective time of the Merger (the
"Effective Time").
Section 2.4. Articles of Incorporation of Surviving Corporation. Effective
at the Effective Time, the Articles of Incorporation of the Company in effect
immediately prior to the Effective Time shall be the Articles of Incorporation
of the Surviving Corporation provided that the Articles shall be amended to
change the name of the Surviving Corporation to "PhyMed Diagnostic Imagining
Center Dallas, Inc." and to limit the liability of directors as permitted under
the Texas Business Corporation Act.
Section 2.5. Bylaws of Surviving Corporation. The Bylaws of Tatonka Sub in
effect immediately prior to the Effective Time shall be the Bylaws of the
Surviving Corporation without any amendment or modification as a result of the
Merger, until duly amended in accordance with applicable laws.
Section 2.6. Directors of the Surviving Corporation. The persons who are
directors of the Company immediately prior to the Effective Time shall submit a
written resignation in form and substance acceptable to Tatonka, effective as of
the Effective Time. The directors of the Surviving Corporation following the
Effective Time shall be set forth in Exhibit 2.6.
Section 2.7. Officers of the Surviving Corporation. The persons who are
officers of the Company immediately prior to the Effective Time shall submit a
written resignation in form and substance acceptable to Tatonka, effective as of
the Effective Time. The officers of the Surviving Corporation following the
Effective Time shall be set forth in Exhibit 2.7.
Section 2.8. Conversion of Company Common Stock. The manner of converting
shares of Company Common Stock in the Merger shall be as follows:
(a) As a result of the Merger and without any action on the part of the
holder thereof,
6
<PAGE>
(i) all 500 shares of Company Common Stock held by Barker at
the Effective Time shall cease to be outstanding and shall be canceled and
retired and shall cease to exist, and the certificate or certificates
representing shares of Company Common Stock held by Barker shall thereafter
cease to have any rights with respect to such shares of Company Common
Stock, except the right to receive validly issued, fully paid and
nonassessable shares of Tatonka Common Stock as determined in accordance
with the provisions of Exhibit A attached hereto; and
(ii) 140 of the 300 shares of Company Common Stock held by the
ESOP at the Effective Time shall cease to be outstanding and shall be
canceled and retired and shall cease to exist, and the certificate or
certificates representing 140 of the 300 shares of Company Common Stock
held by the ESOP shall thereafter cease to have any rights with respect to
such shares of Company Common Stock, except the right to receive validly
issued, fully paid and nonassessable shares of Tatonka Common Stock as
determined in accordance with the provisions of Exhibit A attached hereto;
such shares of Tatonka Common Stock are referred to as the "Merger
Consideration".
Tatonka has 50,000,000 shares of Common Stock authorized for issuance and
9,916,487 shares issued and outstanding or reserved for issuance. To the extent
that the application of this subsection would result in the issuance of more
than 50,000,000 shares, the excess over 50,000,000 shall not be issued until
such time as the Tatonka stockholders have approved an appropriate amendment to
Tatonka's Certificate of Incorporation. Prior to such approval, the Stockholders
shall have a contractual right pursuant to this Agreement and the Articles of
Merger filed with the Secretary of State of Texas to receive such excess shares,
subject to such required stockholder approval.
The parties to this Agreement contemplate that the Board of Directors and
stockholders of Tatonka will approve an amendment to Tatonka's Certificate of
Incorporation approving a 1-for-10 reverse stock split. Upon the effectiveness
of such reverse stock split, the shares which have been issued to the
Stockholders at the Effective Time will represent one-tenth (1/10th) as many
shares as when issued at the Effective Time, and the unissued number of shares
which Tatonka will still have a contractual obligation to issue will also
thereafter become one-tenth (1/10th) as many shares and will be immediately
issued because Tatonka will then have a sufficient number of authorized but
unissued shares to issue for this purpose.
(b) Each share of Company Common Stock held in the Company's
treasury, if any, at the Effective Time, by virtue of the Merger, shall be
canceled and retired without payment of any consideration therefor and shall
cease to exist.
(c) Each Company Right outstanding at the Effective Time shall be
terminated and canceled, without payment of any consideration therefor, and
shall cease to exist.
(d) Each share of common stock of Tatonka Sub issued and outstanding
at the Effective Time shall be converted to one share of Company Common Stock.
(e) At the Effective Time, each share of Tatonka Common Stock issued
and
7
<PAGE>
outstanding as of the Effective Time shall, by virtue of the Merger and without
any action on the part of the holder thereof, continue unchanged and remain
outstanding as a validly issued, fully paid and nonassessable share of Tatonka
Common Stock.
Section 2.9. Exchange of Certificates Representing Shares of the Company
Common Stock.
(a) At or after the Effective Time and at the Closing (i) the
Stockholders, as holders of a certificate or certificates representing shares of
the Company's Common Stock to be surrendered pursuant to Section 2.8, shall upon
surrender of each certificate or certificates (or completion of appropriate
affidavit of lost certificate and indemnity) receive such allocation of Merger
Consideration as determined in accordance with the provisions of Exhibit A
attached hereto; and (ii) until each such certificate or certificates
representing Company Common Stock have been surrendered by the Stockholders, the
certificates for Company Common Stock to be surrendered pursuant to Section 2.8
shall, for all purposes, represent solely the right to receive Merger
Consideration as determined in accordance with the provisions of Exhibit A
attached hereto and Section 2.8 hereof, if applicable. At the Effective Time,
each share of Company Common Stock converted into Merger Consideration shall by
virtue of the Merger and without any action on the part of the holders thereof,
cease to be outstanding, be canceled and returned and all shares of Tatonka
Common Stock issuable to the Stockholders in the Merger as part of the Merger
Consideration shall be deemed for all purposes to have been issued by Tatonka at
the Effective Time.
(b) Each Stockholder shall deliver to Tatonka at the Closing the
certificates representing Company Common Stock owned by him, her or it and to be
surrendered pursuant to Section 2.8, duly endorsed in blank by the Stockholder,
or accompanied by duly executed stock powers in blank, and with all necessary
transfer tax and other revenue stamps, acquired at the Stockholder's expense,
affixed and canceled. Each Stockholder agrees to cure any deficiencies with
respect to the endorsement of the certificates or other documents of conveyance
with respect to such Company Common Stock or with respect to the stock powers
accompanying any Company Common Stock. Upon such delivery (or completion of
appropriate affidavit of lost certificate and indemnity), each Stockholder shall
receive in exchange therefor the Merger Consideration pursuant to Exhibit A and
Section 2.8 hereof, if applicable.
(c) The foregoing provisions shall not apply to the 160 shares of
Company Common Stock retained by the ESOP, which shares shall remain properly
outstanding and shall retain all rights, privileges and designations applicable
to Company Common Stock immediately preceding the Merger.
Section 2.10. Fractional Shares. No fractional shares of Tatonka Common
Stock will be issued. Any fractional share of Tatonka Common Stock that would
otherwise be issuable as part of the Merger Consideration shall rounded to the
nearest whole share of Tatonka Common Stock.
Section 2.11 Percentage Protection Provision. The parties to this Agreement
agree that they are entering into this Agreement with the intention that Barker
and the ESOP will
8
<PAGE>
have at least 87.5% of the shares of Tatonka Common Stock outstanding after (a)
the Effective Time and (b) the conversion of all the Tatonka Preferred Stock,
but before the exercise of any of the three stock options contemplated to be
issued by Tatonka (after the Effective Time) and referred to in Section 4.4 of
this Agreement. The numbers of shares of Tatonka Common Stock set forth on
Exhibit A as being issued to Barker and the ESOP at the Effective Time are based
on the assumptions that (a) no more than 9,015,556 shares of Tatonka Common
Stock, as presently constituted, will be outstanding at the Effective Time
(exclusive of any shares that may be issued upon conversion of Tatonka Preferred
Stock prior to the Effective Time), (b) no more than 900,931 shares will be
issued upon conversion of all the Tatonka Preferred Stock, (c) no other shares
of Tatonka Common Stock will be issued by virtue of any rights to receive any
shares of Tatonka Common Stock or other securities of Tatonka that exist at the
date of this Agreement or will exist at the Effective Time, and (d) the
aggregate of 9,916,487 shares enumerated in (a) and (b) above will constitute no
more than 12.5% of the shares of Tatonka Common Stock outstanding after the
events described above.
The parties to this Agreement covenant and agree that if more than the
9,916,487 shares of Tatonka Common Stock referred to in the foregoing paragraph
are ultimately issued by Tatonka as a consequence of the matters referred to in
such paragraph, Tatonka shall issue to Barker and the ESOP, pro rata, such
additional number of shares of Tatonka Common Stock as shall be necessary to
increase their collective ownership percentage of all shares of Tatonka Common
Stock outstanding after the events described above to 87.5%.
ARTICLE III
REPRESENTATIONS AND WARRANTIES OF THE COMPANY
As an inducement to Tatonka and Tatonka Sub to enter into this Agreement
and to consummate the Merger and except as set forth in the Disclosure Schedules
attached to this Agreement and incorporated by this reference, the Company
represents and warrants to Tatonka and Tatonka Sub both as of this date and as
of the Effective Time as follows:
Section 3.1. Organization and Good Standing; Qualification. The Company is
a corporation duly organized, validly existing and in good standing under the
laws of its state of incorporation, with all requisite corporate power and
authority to own, operate and lease its assets and properties and to carry on
its business as currently conducted. The Company and each Company Subsidiary is
in good standing in each jurisdiction where the character of the property owned
or leased by it or the nature of its activities makes such qualification
necessary, except where such failure to be so qualified or in good standing
would not have a Material Adverse Effect on the Company. Copies of the articles
or certificates of incorporation and all amendments thereto of the Company and
each Company Subsidiary and the bylaws of the Company and each Company
Subsidiary, as amended, and copies of the corporate minutes of the Company, all
of which have been or will be made available to Tatonka for review, are true and
complete as in effect on the date of this Agreement, and in the case of the
corporate minutes, accurately reflect all material proceedings of the
Stockholders and directors of the Company (and all committees thereof). The
stock record
9
<PAGE>
books of the Company, which have been or will be made available to Tatonka for
review, contain true, complete and accurate records of the stock ownership of
record of the Company and the transfer record of the shares of its capital
stock.
Section 3.2. Authorization and Validity. The Company has all requisite
corporate power to enter into this Agreement and all other agreements entered
into in connection with the transactions contemplated hereby and to consummate
the transactions contemplated hereby. The execution, delivery and, subject to
approval of this Agreement and the Merger by the Stockholders, performance by
the Company of this Agreement and the agreements contemplated in this Agreement,
and the consummation by the Company of the transactions contemplated hereby and
thereby are within the Company's respective corporate powers and have been duly
authorized by all necessary action on the part of the Company's Board of
Directors. Subject to the approval of this Agreement and the Merger by the
Stockholders, this Agreement has been duly executed by the Company, and this
Agreement and all other agreements and obligations entered into and undertaken
in connection with the transactions contemplated hereby to which the Company is
a party constitute, or upon execution will constitute, valid and binding
agreements of the Company, enforceable against it in accordance with their
respective terms, except as enforceability may be limited by bankruptcy or other
laws affecting the enforcement of creditors' rights generally, or by general
equity principles, or by public policy.
Section 3.3. Governmental Authorization. Other than complying with the
provisions of the applicable state corporate laws regarding the approval of the
Merger and the filing of the Articles of Merger (as contemplated by Section 2.3)
and any other required documents related to the Merger, and other than consents,
filings or notifications required to be made or obtained solely by Tatonka or
Tatonka Sub, the execution, delivery and performance by the Company of this
Agreement and the agreements provided for in this Agreement, and the
consummation of the transactions contemplated hereby and thereby by the Company
require no action by or in respect of, or filing with, any governmental body,
agency, official or authority.
Section 3.4. Capitalization. The authorized capital stock of the Company
consists of 1,000 shares of the Company Common Stock, of which 800 shares are
issued and outstanding. Barker owns of record and beneficially 500 shares of the
Company Common Stock, and the ESOP owns of record and beneficially 300 shares of
the Company Common Stock. The Stockholders collectively are and will be
immediately prior to the Effective Time the record and beneficial owners of all
the issued and outstanding Company Common Stock, in such respective amounts.
Except for pledges by the Stockholders made in connection with the purchase of
Patrick Luckett's shares (whose consent is necessary to permit receipt of the
Merger Consideration), the Company Common Stock held by the Stockholders is free
and clear of all Encumbrances. Each outstanding share of Company Common Stock
has been legally and validly issued and is fully paid and nonassessable, and was
issued pursuant to a valid exemption from registration under (i) the Securities
Act of 1933, as amended, and (ii) all applicable state securities laws. No
shares of Company Common Stock are owned by the Company in treasury. No shares
of Company Common Stock have been issued or disposed
10
<PAGE>
of in violation of any preemptive rights, rights of first refusal or similar
rights of any of the Stockholders. Other than Company Common Stock, the Company
has no securities, bonds, debentures, notes or other obligations the holders of
which have the right to vote (or are convertible into or exercisable for
securities having the right to vote) with the Stockholders on any matter.
Section 3.5. Transactions in Capital Stock. There exist no Company Rights.
The Company has no obligation (contingent or otherwise) to purchase, redeem or
otherwise acquire any of its equity securities or any interests therein or to
pay any dividend or make any distribution in respect thereof. Neither the equity
structure of the Company nor the relative ownership of shares among any of its
Stockholders has been altered or changed in contemplation of the Merger within
the two years preceding the date of this Agreement.
Section 3.6. Continuity of Business Enterprise. There has not been any
sale, distribution or spin-off of significant assets of the Company or any of
its Affiliates other than in the ordinary course of business within the two
years preceding the date of this Agreement.
Section 3.7. Subsidiaries and Investments. The Company does not own,
directly or indirectly, any capital stock or other equity, ownership or
proprietary interest in any other corporation, partnership, association, trust,
joint venture or other entity (each a "Company Subsidiary").
Section 3.8. Absence of Conflicting Agreements or Required Consents.
Subject to approval of this Agreement and the Merger by the Stockholders of the
Company and the consent of the payee under the ESOP, the execution, delivery and
performance by the Company of this Agreement and any other documents
contemplated hereby (with or without the giving of notice, the lapse of time, or
both): (i) do not require the consent of any governmental or regulatory body or
authority or any other third party except for such consents, for which the
failure to obtain would not result in a Material Adverse Effect on the Company;
(ii) will not conflict with or result in a violation of any provision of the
Company's articles or certificate of incorporation or bylaws, (iii) will not
conflict with, result in a violation of, or constitute a default under any law,
rule, ordinance, regulation or any ruling, decree, determination, award,
judgment, order or injunction of any court or governmental instrumentality which
is applicable to the Company or by which the Company or its properties are
subject or bound; (iv) will not conflict with, constitute grounds for
termination of, result in a breach of, constitute a default under, require any
notice under, or accelerate or modify, or permit any person to accelerate or
modify, any performance required by the terms of any agreement, instrument,
license or permit, to which the Company is a party or by which the Company or
any of its properties are subject or bound except for such conflict,
termination, breach or default, the occurrence of which would not result in a
Material Adverse Effect on the Company; and (v) except as contemplated by this
Agreement, will not create any Encumbrance or restriction upon the Company
Common Stock or any of the assets or properties of the Company.
Section 3.9. Absence of Changes. Except as permitted or contemplated by
this Agreement, since December 31, 1997, the Company has conducted its business
only in the
11
<PAGE>
ordinary course and has not:
(a) suffered any change or changes in its working capital, condition
(financial or otherwise), assets, liabilities, reserves, business or operations
(whether or not covered by insurance) that individually or in the aggregate has
had or could reasonably be expected to have a Material Adverse Effect on the
Company;
(b) paid, discharged or satisfied any material liability, other than
the payment, discharge or satisfaction of liabilities in the ordinary course of
business;
(c) written off as uncollectible any receivable, except for
write-offs in the ordinary course of business;
(d) except in the ordinary course of business and consistent with
past practice, canceled or compromised any debts or waived or permitted to lapse
any claims or rights or sold, transferred or otherwise disposed of any of its
properties or assets;
(e) entered into any commitment or transaction not in the ordinary
course of business that is material to the Company, taken as a whole, or made
any capital expenditure or commitment in excess of $25,000;
(f) made any change in any method of accounting or accounting
practice, credit practices, collection policies, or payment policies;
(g) except in the ordinary course of business consistent with past
practice, incurred any liabilities or obligations (absolute, accrued or
contingent) in excess of $10,000 individually or $25,000 in the aggregate;
(h) mortgaged, pledged, subjected or agreed to subject, any of its
assets, tangible or intangible, to any claim or Encumbrance, except for liens
for current personal property taxes not yet due and payable for mechanics,
landlords, materialmen, and other statutory liens, purchase money security
interests, sale-leaseback interests granted and all other Encumbrances granted
in similar transactions;
(i) sold, redeemed, acquired or otherwise transferred any equity or
other interest in itself;
(j) increased any salaries, wages or any employee benefits for any
employee of the Company, except in the ordinary course of business and
consistent with past practice;
(k) hired, committed to hire or terminated any employee except in
the ordinary course of business;
(l) declared, set aside or made any payments, dividends or other
distributions to any Stockholder or any other holder of capital stock of the
Company (except as expressly contemplated in this Agreement); or
(m) agreed, whether in writing or otherwise, to take any action
described in this Section 3.9.
Section 3.10. No Undisclosed Liabilities. The Company does not have any
liabilities or obligations of any nature, whether accrued, absolute, contingent
or otherwise, asserted or
12
<PAGE>
unasserted except for liabilities or obligations reflected or reserved against
in the Company's Current Balance Sheet.
Section 3.11. Litigation and Claims. There are no claims, lawsuits,
actions, arbitrations, administrative or other proceedings, governmental
investigations or inquiries pending or, to the knowledge of the Company,
threatened against, or affecting the Company, any Company Subsidiary, any
Stockholder or any licensed professional or other individual affiliated with the
Company affecting or that would reasonably be likely to affect the Company
Common Stock or the operations, business condition, (financial or otherwise), or
results of operations of the Company which (i) if successful, may, individually
or in the aggregate, have a Material Adverse Effect on the Company or (ii) could
adversely affect the ability of the Company or any Company Subsidiary to effect
the transactions contemplated hereby, and to the knowledge of the Company there
is no basis for any such action or any state of facts or occurrence of any event
which would reasonably be likely to give rise to the foregoing. There are no
unsatisfied judgments against the Company or any Company Subsidiary or any
licensed professional or other individual affiliated with the Company or any
Company Subsidiary relating to services provided on behalf of the Company or any
Company Subsidiary or any consent decrees to which any of the foregoing is
subject. Each of the matters, if any, set forth in this Section 3.11 is fully
covered by policies of insurance of the Company or any Company Subsidiary as in
effect on the date hereof.
Section 3.12. No Violation of Law. Neither the Company nor any Company
Subsidiary has been, nor shall be as of the Effective Time (by virtue of any
action, omission to act, contract to which it is a party or any occurrence or
state of facts whatsoever), in violation of any applicable local, state or
Federal law, ordinance, regulation, order, injunction or decree, or any other
requirement of any governmental body, agency, authority or court binding on it,
or relating to its properties, assets or business or its advertising, sales or
pricing practices, except for violations which, individually or in the
aggregate, would not reasonably be expected to have a Material Adverse Effect on
the Company.
Section 3.13. Lease Agreements. The Disclosure Schedules contain a true,
accurate and complete list of all the lease agreements and license agreements to
which the Company or any Company Subsidiary is a party and pursuant to which the
Company or any Company Subsidiary leases (whether as lessor or lessee) or
licenses (whether as licensor or licensee) any real or personal property related
to the operation of its business and which requires payments in excess of
$12,000 per year (the "Lease Agreements"). The Company has delivered to Tatonka
true and complete copies of all of the Lease Agreements. Each Lease Agreement is
valid, effective and in full force in accordance with its terms, and there is
not under any such lease (i) any existing or claimed material default by the
Company or any Company Subsidiary (as applicable) or event of material default
or event which with notice or lapse of time, or both, would constitute a
material default by the Company or any Company Subsidiary (as applicable) and,
individually or in the aggregate, may reasonably result in a Material Adverse
Effect on the Company, or, (ii) to the knowledge of the Company, any existing
material default by any other party under any of the Lease Agreements or any
event of material default or event which with notice or lapse of time, or both,
would constitute a material default by
13
<PAGE>
any such party. To the knowledge of the Company, there is no pending or
threatened reassessment of any property covered by the Lease Agreements. The
Company or any Company Subsidiary will use reasonable good faith efforts to
obtain, prior to the Effective Time, the consent of each landlord or lessor
whose consent is required in connection with the Merger and will use reasonable
good faith efforts to deliver to Tatonka or Tatonka Sub in writing such consents
as are necessary to effect the Merger. The Company has a good, clear, valid and
enforceable leasehold interest under each of the Lease Agreements. To the best
of the Company's knowledge, the Lease Agreements comply with the exceptions to
ownership interests and compensation arrangements set out in 42 U.S.C. Section
1395nn, 42 C.F.R. Section 1001.952, and any similar applicable state law safe
harbor or other exemption provisions.
Section 3.14. Real and Personal Property.
(a) Neither the Company nor any Company Subsidiary owns any interest
(other than the Lease Agreements) in real property.
(b) The Company and any Company Subsidiary (i) has good title to all
of its properties and assets (real, personal and mixed, tangible and intangible)
and any rights or interests therein which it purports to own including, without
limitation, all the property and assets reflected in the Company Financial
Statements; and (ii) owns such rights, interests, assets and property free and
clear of all Encumbrances, title defects or objections (except for taxes not yet
due and payable). The personal property presently used in connection with the
operation of the business of the Company and the Company Subsidiaries
constitutes the necessary personal property assets to continue operation of the
Company and any Company Subsidiary.
Section 3.15. Indebtedness for Borrowed Money. Except for trade payables
incurred in the ordinary course of business or as reflected in the Company
Financial Statements or the Disclosure Schedules, the Company does not have any
direct or indirect indebtedness for borrowed money, including indebtedness by
way of lease-purchase arrangements or guarantees, and is not obligated in any
manner (actual or contingent) to assume or guarantee any indebtedness or
obligation of another Person.
Section 3.16. Contracts and Commitments.
(a) The Disclosure Schedules contain a true, accurate and complete
list, and the Company has delivered to Tatonka true and complete copies, of each
contract, agreement and other instrument requiring the Company to make future
payments of $10,000 in any fiscal year or $25,000 in the aggregate (other than
insurance contracts identified in Section 3.22 or Lease Agreements identified in
Section 3.13) to which the Company is a party or by which it or any of its
properties or assets are bound including, without limitation, (i) all agreements
between the Company, on the one hand, and any Payor, government entity,
provider, hospital, health maintenance organization, other managed care
organization or other third-party provider, on the other hand, then in effect
relating to the provision of medical, diagnostic imaging or consulting services,
treatments, patient referrals or other similar activities, (ii) all indentures,
mortgages, notes, loan or credit agreements and other agreements and obligations
14
<PAGE>
relating to the borrowing of money or to the direct or indirect guarantee or
assumption of obligations of third parties requiring the Company to make, or
setting forth conditions under which the Company would be required to make,
aggregate future payments in excess of $10,000 in any fiscal year or $25,000 in
the aggregate, (iii) all agreements for capital improvements or acquisitions
involving an amount of $75,000 in any fiscal year or $75,000 in the aggregate,
(iv) all agreements containing a covenant limiting the freedom of the Company
(or any provider employee of the Company) to compete in any line of business
with any person or entity or in any geographic area or (v) all written contracts
and commitments providing for future payments by the Company in excess of
$10,000 in any fiscal year or $25,000 in the aggregate and that are not
cancelable by providing notice of 60 days or less. All such contracts,
agreements or other instruments are in full force and effect, there has been no
threatened cancellation thereof, there are no outstanding disputes thereunder,
each is with unrelated third parties and was entered into on an arms-length
basis and, assuming the receipt of the appropriate consents, all will continue
to be binding in accordance with their terms after consummation of the
transaction contemplated in this Agreement; and there are no contracts,
agreements or other instruments to which the Company is a party or is bound
(other than physician employment contracts and insurance policies) which in any
of the foregoing events could singularly or in the aggregate have a Material
Adverse Effect on the value to Tatonka or Tatonka Sub of the Company. In every
instance where consent is necessary, the Company shall, on or before the Closing
Date, use reasonable good faith efforts to obtain and deliver to Tatonka or
Tatonka Sub in writing, effective as of the Closing Date, such consents as are
necessary to enable the Surviving Corporation to enjoy all of the rights now
enjoyed by the Company under such contracts. Any and all such consents shall be
in a form reasonably acceptable to Tatonka and shall contain an acknowledgment
by the consenting party that the Company has fully complied with and is not in
default under any provision of the particular contract or agreement. Except as
set forth in Schedule 3.16, no contract with a health care provider or Payor has
been materially amended or terminated within the last 12 months.
(b) The Company (i) has not received notice of any plan or intention
of any other party to exercise any right to cancel or terminate any contract,
agreement or instrument required to be disclosed pursuant to Section 3.16(a),
and to the knowledge of the Company there are no fact(s) that would justify the
exercise of such a right; and (ii) does not currently contemplate, or have
reason to believe any other Person currently contemplates, any amendment or
change to any such contract, agreement or instrument.
Section 3.17. Employee Matters. The Company is not currently a party to any
employment contract except for its employment contract with Barker and oral
employment agreements which are terminable at will, consulting or collective
bargaining contracts, deferred compensation, pension plan (as defined in Section
3(2) of the Employee Retirement Income Security Act of 1974, as amended, and all
rules and regulations from time to time promulgated thereunder ("ERISA")),
profit sharing, bonus, stock option, stock purchase or other nonqualified
benefit or compensation commitments, benefit plans, arrangements or plans
(whether written or oral), including all welfare plans (as defined in Section
3(1) of ERISA) of or pertaining to the Company and any of its present or former
employees, or any predecessors in interest, except for the ESOP and standard
benefits afforded employees such
15
<PAGE>
as paid vacation, holiday and sick leave, health, dental, disability and group
life insurance, and benefits mandated by Federal or state law for employees
generally.
Section 3.18. Labor Relations.
(a) To the knowledge of the Company, the Company is in material
compliance with all applicable laws respecting employment and employment
practices, terms and conditions of employment, wages and hours, occupational
safety and health, and is not engaged in any unfair labor practice within the
meaning of Section 8 of the National Labor Relations Act;
(b) To the knowledge of the Company, there is no unfair labor
practice, charge or complaint or any other employment-related matter against or
involving the Company pending or threatened before the National Labor Relations
Board or any Federal, state or local agency, authority or court;
(c) To the knowledge of the Company, there are no charges,
investigations, administrative proceedings or formal complaints of
discrimination (including discrimination based upon sex, age, marital status,
race, national origin, the making of workers' compensation claims, sexual
preference, handicap or veteran status) pending or threatened before the Equal
Employment Opportunity Commission or any Federal, state or local agency or court
against the Company. There have been no governmental audits of the equal
employment opportunity practices of the Company and, to the knowledge of the
Company, no basis for any such audit exists which, if conducted would result in
a Material Adverse Effect on the Company;
(d) The Company is in material compliance with the Immigration
Reform and Control Act of 1986, as amended, and all applicable regulations
promulgated thereunder; and
(e) To the knowledge of the Company, there are no inquiries,
investigations or monitoring activities of any licensed, registered, or
certified professional personnel employed or retained by, credentialed or
privileged, or otherwise affiliated with the Company pending or threatened by
any state professional board or agency charged with regulating the professional
activities of health care practitioners.
Section 3.19. Employee Benefit Plans.
(a) Identification. The Disclosure Schedules contain a complete and
accurate list of all employee benefit plans (within the meaning of Section 3(3)
of ERISA) sponsored by the Company or to which the Company contributes on behalf
of its employees and all employee benefit plans previously sponsored or
contributed to on behalf of its employees within the three years preceding the
date hereof (the "Employee Benefit Plans"). The Company has provided to Tatonka
copies of all plan documents (as they may have been amended to the date hereof),
determination letters, pending determination letter applications, trust
instruments, insurance contracts or policies related to an Employee Benefit
Plan, administrative services contracts, annual reports, actuarial valuations,
summary plan descriptions, summaries of material modifications, administrative
forms and other documents that constitute a part of or are incident to the
administration of the Employee Benefit Plans. In addition, the Company has
provided or made available to Tatonka a written description of
16
<PAGE>
all existing practices engaged in by the Company that constitute Employee
Benefit Plans. Subject to the requirements of ERISA, each of the Employee
Benefit Plans can be terminated or amended at will by the Company without any
further liability or obligation on the part of such entity to make further
contributions or payments in connection therewith following such termination. No
unwritten amendment exists with respect to any Employee Benefit Plan.
(b) Administration. Each Employee Benefit Plan has been administered
and maintained in compliance with all applicable laws, rules and regulations,
except where the failure to be in compliance would not, individually or in the
aggregate, result in a Material Adverse Effect.
(c) Examinations. The Company has not received any notice that any
Employee Benefit Plan is currently the subject of an audit, investigation,
enforcement action or other similar proceeding conducted by any state or Federal
agency or authority.
(d) Prohibited Transactions. No prohibited transactions (within the
meaning of Section 4975 of the Code or Section 406 of ERISA) have occurred with
respect to any Employee Benefit Plan. There has been no breach of any duty under
ERISA or applicable law (including, without limitation, any health care
contractor requirements or any other tax law requirements, or conditions to
favorable tax treatment, applicable to such plan), which would be reasonably
likely to result, directly or indirectly, (including through any obligation of
indemnification or contribution), in any taxes, penalties or other liability to
Tatonka or any of its Affiliates.
(e) Claims and Litigation. No pending or, to the Company's
knowledge, threatened, claims, suits or other proceedings exist with respect to
any Employee Benefit Plan other than normal benefit claims filed by participants
or beneficiaries.
(f) Qualification. The Company has received a favorable
determination letter or ruling from the IRS for each of the Employee Benefit
Plans intended to be qualified within the meaning of Section 401(a) or 501(c)(9)
of the Code and/or tax-exempt within the meaning of Section 501(a) of the Code
and, to the best knowledge of the Company and each Stockholder, has been
continually qualified under the applicable Section of the Code since the
Effective Time of such Employee Benefit Plan. No proceedings exist or, to the
Company's knowledge, have been threatened that could result in the revocation of
any such favorable determination letter or ruling.
(g) Funding Status. No accumulated funding deficiency (within the
meaning of Section 412 of the Code), whether waived or unwaived, exists with
respect to any Employee Benefit Plan or any plan sponsored by any member of a
controlled group (within the meaning of Section 412(n)(6)(B) of the Code) in
which the Company is a member (a "Controlled Group"). With respect to each
Employee Benefit Plan subject to Title IV of ERISA, the assets of each such plan
are at least equal in value to the present value of accrued benefits determined
on an ongoing basis as of the date hereof. With respect to each Employee Benefit
Plan described in Section 501(c)(9) of the Code, the assets of each such plan
are at least equal in value to the present value of accrued benefits, based upon
the most recent actuarial valuation as of a date no more than 90 days prior to
the date hereof. The Disclosure
17
<PAGE>
Schedules contain a complete and accurate statement of all actuarial assumptions
applied to determine the present value of accrued benefits under all Employee
Benefit Plans subject to actuarial assumptions.
(h) Excise Taxes. Neither the Company nor any member of a Controlled
Group has any liability to pay excise taxes with respect to any Employee Benefit
Plan under applicable provisions of the Code or ERISA.
(i) Multiemployer Plans. Neither the Company nor any member of a
Controlled Group is or ever has been obligated to contribute to a multiemployer
plan within the meaning of Section 3(37) of ERISA or any other Employee Benefit
Plan which has been subject to Title IV of ERISA or Section 412 of the Code.
(j) PBGC. No facts or circumstances are known to the Company that
would result in the imposition of liability against Tatonka, Tatonka Sub or any
of its Affiliates by the Pension Benefit Guaranty Corporation ("PBGC") as a
result of any act or omission by the Company or any member of a Controlled
Group. No reportable event (within the meaning of Section 4043 of ERISA) for
which the notice requirement has not been waived has occurred with respect to
any Employee Benefit Plan subject to the requirements of Title IV of ERISA.
(k) Retirees. The Company has no obligation or commitment to provide
medical, dental or life insurance benefits to or on behalf of any of its
employees who may retire or any of its former employees who have retired except
as may be required pursuant to the continuation of coverage provisions of
Section 4980B of the Code and the applicable provisions of ERISA.
(l) Other Compensation Arrangements. Neither the Company nor, to the
Company's knowledge, any Stockholder or Physician Employee is a party to any
compensation or debt arrangement with any Person relating to the provision of
health care related services other than arrangements with the Company.
Section 3.20. Environmental Matters.
(a) Neither the Company nor any Company Subsidiary has, within the
five years preceding the date hereof, through the Effective Time, received from
any Federal, state or local governmental body, agency, authority or entity, or
any other Person, any written notice, demand, citation, summons, complaint or
order or any notice of any penalty, lien or assessment, and to the knowledge of
the Company no investigation or review is pending by any governmental entity,
with respect to any (i) alleged violation by the Company of any Environmental
Law (as defined in subsection (e) below) (ii) alleged failure by the Company to
have any environmental permit, certificate, license, approval, registration or
authorization required pursuant to any Environmental Law in connection with the
conduct of its business; or (iii) alleged illegal Regulated Activity (as defined
in subsection (e) below) by the Company.
(b) Neither the Company nor any Company Subsidiary has used,
transported, disposed of or arranged for the disposal of (as those terms are
defined in and construed under the Comprehensive Environmental Response,
Compensation and Liability Act) any Hazardous
18
<PAGE>
Substance (as defined in this Agreement) that would be reasonably likely to give
rise to any Environmental Liabilities (as defined in subsection (e) below) for
the Company under any applicable Environmental Law that had, or would reasonably
be likely to have, a Material Adverse Effect on the Company. Neither the Company
nor any Company Subsidiary has engaged in any activity or failed to undertake
any activity which action or failure to act has given, or would reasonably be
likely to give, rise to any Environmental Liabilities or enforcement action by
any Federal, state or local regulatory agency or authority, or has resulted, or
would reasonably be likely to result, in any fine or penalty imposed pursuant to
any Environmental Law. Schedule 3.20(b) discloses any known presence of asbestos
in or on the Company's or any Company Subsidiary's owned or leased premises. To
the knowledge of the Company, there is no friable asbestos in or on the
Company's or any Company Subsidiary's owned or leased premises.
(c) For the purposes of this Section 3.20, the following terms have
the following meanings:
"Environmental Laws" shall mean any Federal, state or local laws,
ordinances, codes, regulations, rules, policies and orders (including
without limitation, Medical Waste Laws) that are intended to assure the
protection of the environment, or that classify, regulate, call for the
remediation of, require reporting with respect to, or list or define air,
water, groundwater, solid waste, hazardous, toxic, or radioactive
substances, materials, wastes, pollutants or contaminants, or which are
intended to assure the safety of employees, workers or other persons,
including the public in each case as in effect on the date hereof.
"Environmental Liabilities" shall mean all liabilities of the
Company or any Company Subsidiary, whether contingent or fixed, which (i)
have arisen, or would reasonably be likely to arise, under Environmental
Laws and (ii) relate to actions occurring or conditions existing on or
prior to the date hereof or the Effective Time.
"Hazardous Substances" shall mean any toxic or hazardous substances,
material or waste, including Medical Waste, or any pollutant or
contaminant, or infectious or radioactive substance or material, including
without limitation, those substances, materials and wastes defined in or
regulated under any Environmental Laws.
"Regulated Activity" shall mean any generation, treatment, storage,
recycling, transportation, disposal or release of any Hazardous Substances.
Section 3.21. Filing Reports. All returns, reports, plans and filings of
any kind or nature necessary to be filed by the Company with any governmental
agency or authority have been properly completed and timely filed in compliance
with all applicable requirements, except where failure to so file would not have
a Material Adverse Effect on the Company.
Section 3.22. Insurance Policies. The Disclosure Schedules list and briefly
describe the Company's policies of insurance to which the Company or any Company
Subsidiary is a party or under which the Company or any Company Subsidiary,
officer or director thereof is or has been covered at any time during the last
five years preceding the date of this Agreement relating to the business of the
Company or any Company Subsidiary (the
19
<PAGE>
"Insurance Policies"). All of the Insurance Policies are valid, outstanding and
enforceable policies, except as may be limited by applicable bankruptcy,
insolvency or similar laws affecting creditors' rights generally or the
availability of equitable remedies and all premiums with respect thereto which
are due and payable are currently paid. All Insurance Policies currently
maintained by the Company or any Company Subsidiary ("Current Policies") taken
together, (i) are believed to provide adequate insurance coverage for the
assets, properties and operations of the Company and its Affiliates for all
risks normally insured against by a Person carrying on a substantially similar
business or businesses as the Company and its Affiliates, (ii) are sufficient
for compliance with legal and contractual requirements to which the Company or
any of its Affiliates is a party or by which any of them may be bound, and (iii)
shall be maintained in force (including the payment of all premiums and
compliance with their terms) without interruption up to and including the
Closing Date. True, complete and correct copies of all Insurance Policies have
been provided to Tatonka. Neither the Company nor any Company Subsidiary nor any
officer or director thereof has received any notice or other written
communication from any issuer of any Current Policy canceling such policy,
materially increasing any deductibles or retained amounts thereunder, or
materially increasing the annual or other premiums payable thereunder and, to
the knowledge of the Company, no such cancellation or increase of deductibles,
retainages or premiums is threatened. There are no outstanding claims,
settlements or premiums owed against any Insurance Policy, and all required
notices have been given and all known potential or actual claims under any
Insurance Policy have been presented in due and timely fashion. Within the five
years preceding the Agreement, neither the Company nor any Company Subsidiary
has filed a written application for any professional liability insurance
coverage which has been denied by an insurance agency or carrier. The Disclosure
Schedules also set forth a list of all claims under any Insurance Policy in
excess of $10,000 per occurrence filed by the Company or any Company Subsidiary
during the immediately preceding three-year period.
Section 3.23. Licenses, Authorization and Provider Programs.
(a) The Company and each Physician Employee and other licensed
employee or independent contractor of the Company (i) is the holder of all valid
licenses, approvals, orders, consents, permits, registrations, qualifications
and other rights and authorizations required by law, ordinance, regulation or
ruling of any governmental regulatory authority necessary to operate its/his/her
business and (ii) is eligible to participate in and to receive reimbursement
under Titles XVIII and XIX of the Social Security Act (the "Medicare and
Medicaid Programs") and any other programs funded in whole or in part by
Federal, state or local entities for which the Company is eligible
("Governmental Programs"), except that the Company has elected not to enroll in
the Medicare and Medicaid Programs for the current fiscal year. The Company and
the Stockholders and each employee who is required to have a provider number,
has a current provider number for such Governmental Programs and with such
private non-governmental programs (including without limitation any private
insurance program) under which the Company is presently receiving payments
directly or indirectly from any Payor for patient care provided by such licensed
employee or independent contractor (such non-governmental programs called
"Private Programs"). A true, correct and complete list of such licenses, permits
and other authorizations (including, but not limited to
20
<PAGE>
verification of Medicare and Medicaid provider numbers and participating
physician contracts under 1842(h) of the Social Security Act), and provider
agreements, is set forth in the Disclosure Schedules, true, complete and correct
copies of which have been provided to Tatonka. No violation, default, order or
deficiency exists with respect to any of the items listed in the Disclosure
Schedules except for such violations, defaults, orders or deficiencies which
would not be reasonably likely to have a Material Adverse Effect on the Company,
and there is no action pending or to the Company's knowledge recommended by any
state or Federal agencies having jurisdiction over the items listed in the
Disclosure Schedules, either to revoke, withdraw or suspend any material license
or to terminate the participation of the Company in any Governmental Program or
Private Program, and no event has occurred which, with or without notice or
lapse of time, or both, would constitute grounds for a violation, order or
deficiency with respect to any of the items listed in the Disclosure Schedules
to revoke, withdraw or suspend any material license to operate its business as
is presently being conducted by it. To the knowledge of the Company, there has
been no decision not to renew any existing agreement with any provider or Payor
relating to the Company's business as presently being conducted by it. Neither
the Company nor any licensed employee (i) has had his/her/its license, Drug
Enforcement Agency number, or Medicare/Medicaid provider status suspended,
relinquished, terminated or revoked (including orders that have been entered by
any such entities but stayed), (ii) has been reprimanded in writing, sentenced,
or disciplined by any licensing board, state agency, regulatory body or
authority, or Payor (including orders that have been entered by any such
entities but stayed), or (iii) is the subject of an initial or final
determination by any Federal or state authority that could result in any demand
or reimbursement under the Medicare, Medicaid or Government Programs or any
exclusion or which monetary penalty under Federal or state law or (iv) has had a
final judgment or settlement entered against him/her/it in connection with a
malpractice or similar action.
(b) The Company is not required, or for the 72-month period prior to
the Effective Time was not required, to file any cost reports or other reports
with any Governmental Program or Private Program.
Section 3.24. Inspections and Investigations. Neither the right of the
Company nor the right of any licensed professional or other individual
affiliated with the Company to receive reimbursements pursuant to any
Governmental Program or Private Program has been terminated or otherwise
materially and adversely affected as a result of any investigation or action
whether by any Federal or state governmental regulatory authority or other third
party. No licensed professional or other individual affiliated with the business
has, during the past three years prior to the Effective Time, had their license
limited, suspended or revoked by any governmental regulatory authority or
agency, integrated delivery system, trade association, review organization,
accrediting organization or certifying agency (including orders that have been
entered by any such entities but stayed). True, correct and complete copies of
all reports, correspondence, notices and other documents relating to any matter
described or referenced in this Section 3.24 have been provided to Tatonka.
Section 3.25. Proprietary Rights and Information.
21
<PAGE>
(a) Set forth in the Disclosure Schedules is a complete and accurate
list and summary description of the following: (i) all trademarks (registered
and unregistered), trade- names, service marks and other trade designations,
including common law rights, registrations and applications therefor, currently
owned in whole or part, or used by the Company or any Company Subsidiary, (ii)
all patents and applications therefor and inventions and discoveries that may be
patentable currently owned, in whole or in part, or used by the Company or any
Company Subsidiary, (iii) all licenses, royalties, and assignments thereof to
which the Company or any Company Subsidiary are a party (iv) all copyrights (for
published and unpublished works) currently owned in whole or part, or used by
the Company or any Company Subsidiary and (v) other similar agreements relating
to the foregoing to which the Company or any Company Subsidiary is a party
(including expiration date if applicable) (collectively, the "Proprietary
Rights").
(b) The Disclosure Schedules contain a complete and accurate list
and summary description of all agreements relating to technology, trade secrets,
know-how or processes that the Company is licensed or authorized to use by
others (other than technology, know-how or processes generally available to
other health care providers) or which it licenses or authorizes others to use,
true, correct and complete copies of which have been provided to Tatonka. There
are no outstanding and, to the Company's knowledge, any threatened disputes or
disagreements with respect to any such agreement.
(c) The Company owns or has the legal right to use the Proprietary
Rights without conflicting with, infringing or violating the rights of any other
Person. No consent of any person will be required for the use thereof by Tatonka
upon consummation of the transactions contemplated hereby and the Proprietary
Rights are freely transferable. To the knowledge of the Company, no claim has
been asserted by any person to the ownership of or for infringement by the
Company of any Proprietary Right of any other Person, and neither the Company
nor any Stockholder is aware of any valid basis for any such claim. To the best
knowledge of the Company, no proceedings have been threatened which challenge
the Proprietary Rights of the Company. The Company has the right to use, free
and clear of any adverse claims or rights of others, all trade secrets, customer
lists and proprietary information required for the performance and marketing of
all medical services.
Section 3.26. Taxes.
(a) Filing of Tax Returns. The Company has duly and timely filed (in
accordance with any extensions duly granted by the appropriate governmental
agency, if applicable) with the appropriate governmental agencies all Tax
Returns and reports required to be filed with the United States or any state or
any political subdivision thereof or any foreign jurisdiction. All such Tax
Returns or reports are complete and accurate in all material respects and
properly reflect the taxes of the Company for the periods covered thereby.
(b) Payment of Taxes. Except for such items as the Company may be
disputing in good faith by proceedings in compliance with applicable law, which
are described in Schedule 3.26(b), (i) the Company has paid all taxes,
penalties, assessments and interest that have become due with respect to any Tax
Returns that it has filed and has properly accrued on its
22
<PAGE>
books and records in accordance with generally accepted accounting principles
for all of the same that have not yet become due and payable and (ii) the
Company is not delinquent in the payment of any tax, assessment or governmental
charge.
(c) No Pending Deficiencies, Delinquencies, Assessments or Audits.
The Company has not received any notice that any tax deficiency or delinquency
has been asserted against the Company and to the best knowledge of the Company,
there is no threat of such assertion. There is no unpaid assessment, proposal
for additional taxes, deficiency or delinquency in the payment of any of the
taxes of the Company that could reasonably be likely to be asserted by any
taxing authority. There is no taxing authority audit of the Company pending, or
to the actual knowledge of the Company, threatened within the last five years,
and the results of any completed audits are properly reflected in the Company
Financial Statements. Except as provided for on the Company Balance Sheet, the
Company has paid all required Federal, state, or local taxes to the extent that
the same have become due and payable. All Federal, state and local taxes for the
periods subsequently to the Company Balance Sheet date have likewise been paid
or accrued. There are no security interests or liens on any assets of the
Company or any Company Subsidiary which have resulted from any failure to pay
(or alleged failure to pay) taxes.
(d) No Extension of Limitation Period. The Company has not granted
an extension to any taxing authority of the statute of limitation period during
which any tax liability may be assessed or collected.
(e) All Withholding Requirements Satisfied. All monies required to
be withheld by the Company and paid to governmental agencies for all income,
social security, unemployment insurance, sales, excise, use, and other taxes
have been collected or withheld and paid to the respective governmental
agencies.
(f) Foreign Person. Neither the Company nor any Stockholder is a
foreign person, as such term is referred to in Section 1445(f)(3) of the Code
and Treasury Regulations Section 1.1445-2.
(g) Safe Harbor Lease. None of the properties or assets of the
Company constitutes property that the Company, Tatonka, Tatonka Sub or any
Affiliate of Tatonka, will be required to treat as being owned by another person
pursuant to the "Safe Harbor Lease" provisions of Section 168(f)(8) of the Code
prior to repeal by the Tax Equity and Fiscal Responsibility Act of 1982.
(h) Tax Exempt Entity. None of the assets or properties of the
Company are subject to a lease to a "tax exempt entity" as such term is defined
in Section 168(h)(2) of the Code.
(i) Collapsible Corporation. The Company has not at any time
consented to have the provisions of Section 341(f)(2) of the Code apply to it.
(j) Boycotts. The Company has not at any time participated in or
cooperated with any international boycott as defined in Section 999 of the Code.
(k) Parachute Payments. No payment required or contemplated to be
made by the
23
<PAGE>
Company will be characterized as an "excess parachute payment" within the
meaning of Section 280G(b)(1) of the Code.
(l) S Corporation. The Company has not made an election to be taxed
as an "S" corporation under Section 1362(a) of the Code.
(m) Personal Holding Companies. The Company is not or has not been a
personal holding company within the meaning of Section 542 of the Code.
Section 3.27. Related Party Arrangements. The Disclosure Schedules set
forth a description of any interest held, directly or indirectly, by any
officer, director or other Affiliate of the Company in any property, real or
personal or mixed, tangible or intangible, used in or pertaining to the
Company's business and any arrangement or agreement with any such person
concerning the provision of goods or services or other matters pertaining to the
Company's business. There is no commitment to, and no income reflected in the
Company Financial Statements that has been derived from, an Affiliate, and
following the Closing the Company shall not have any obligation of any kind or
designation to any such Affiliate.
Section 3.28. Banking Relations. Set forth in the Disclosure Schedules is a
complete and accurate list of all borrowing and investing arrangements that the
Company has with any bank or other financial institution, indicating with
respect to each relationship the type of arrangement maintained (such as
checking account, borrowing arrangements, safe deposit box, etc.) and the Person
or Persons authorized in respect thereof.
Section 3.29. Fraud and Abuse and Self Referral. Neither the Company nor
any Company Subsidiary has engaged and, to the knowledge of the Company, neither
the Company's officers and directors nor the Physician Employees or other
Persons and entities providing professional services for or on behalf of the
Company have engaged, in any activities which are prohibited under 42 U.S.C.
Sections 1320a 7, 7a or 7b or 42 U.S.C. Section 1395nn (subject to the
exceptions or safe harbor provisions set forth in such legislation), or the
regulations promulgated thereunder or pursuant to similar state or local
statutes or regulations, or which are prohibited by applicable rules of
professional conduct or 18 U.S.C. Sections 24, 287, 371, 664, 669, 1001, 1027,
1035, 1341, 1343, 1347, 1518, 1954, 1956(c)(7)(F) and 3486.
Section 3.30. Restrictions on Business Activities. There is no material
agreement, judgment, injunction, order or decree binding upon the Company, any
Company Subsidiary or officer, director or key employee of the Company or
Company Subsidiary, which has or reasonably could be expected to have the effect
of prohibiting or materially impairing the current business of the Company or
any Company Subsidiary or the continuation of that business in the future, any
acquisition of property by the Company, any Company Subsidiary or the conduct of
business by the Company or any Company Subsidiary.
Section 3.31. Agreements in Full Force and Effect. All contracts,
agreements, plans, leases, policies and licenses referred to, or required to be
referred to, in the Company's Disclosure Schedules delivered hereunder are valid
and binding, and are in full force and effect and are enforceable in accordance
with their terms, except to the extent that the validity or enforceability
thereof may be limited by bankruptcy or other laws affecting the enforcement
24
<PAGE>
of creditors' rights generally, or by general equity principles, or by public
policy. There is no pending or, to the knowledge of the Company, threatened
bankruptcy, insolvency or similar proceeding with respect to any other party to
such agreements, and no event has occurred which (whether with or without
notice, lapse of time or the happening or occurrence of any other event) would
constitute a default thereunder by the Company or any other party thereto.
Section 3.32. Statements True and Correct. No representation or warranty
made by the Company or any Stockholder, nor any statement, certificate,
information, exhibit or instrument to be furnished by the Company or any
Stockholder to Tatonka, Tatonka Sub or any of their respective representatives
pursuant to this Agreement, contains or will contain as of the Effective Time
any untrue statement of material fact or omits or will omit to state a material
fact necessary to make the statements contained herein and therein not
misleading.
Section 3.33. Disclosure Schedules. All Disclosure Schedules required by
this Article III are true, correct and complete in all material respects as of
the date of this Agreement.
Section 3.34. Finders' Fees. No investment banker, broker, finder or other
intermediary has been retained by or is authorized to act on behalf of any of
the Stockholders or the Company who is entitled to any fee or commission upon
consummation of the transactions contemplated by this Agreement or referred to
in this Agreement.
ARTICLE IV
REPRESENTATIONS AND WARRANTIES OF TATONKA
As inducement to the Company and the Stockholders to enter into this
Agreement and to consummate the Merger, Tatonka represents and warrants to the
Company and the Stockholders both as of the date hereof and as of the Effective
Time as follows:
Section 4.1. Organization and Good Standing; Qualification. Tatonka is a
corporation duly organized, validly existing and in good standing under the laws
of the state of Oklahoma, with all requisite corporate power and authority to
own, operate and lease its assets and properties and to carry on its business as
currently conducted. Tatonka is duly qualified to do business as a foreign
corporation and is in good standing in each jurisdiction where the character of
the property owned or leased by it or the nature of its activities makes such
qualification necessary, except where such failure to be so qualified or in good
standing would not have a Material Adverse Effect on Tatonka. Copies of the
certificate of incorporation and all amendments thereto of Tatonka and the
bylaws of Tatonka, as amended, and copies of the corporate minutes of Tatonka
regarding the Merger and the transactions contemplated hereby, all of which have
been or will be made available to the Company for review, are true, correct and
complete as in effect on the date of this Agreement and accurately reflect all
material proceedings of the stockholders and directors of Tatonka (and all
committees thereof) regarding the Merger and the transactions contemplated
hereby. The stock record books of Tatonka, which have been or will be made
available to the Company for review, contain true, complete and accurate records
of the stock ownership of Tatonka and the transfer of the shares of its capital
stock.
Section 4.2. Authorization and Validity. Tatonka has all requisite
corporate power
25
<PAGE>
to execute and deliver this Agreement and to consummate the Merger and the
transactions contemplated hereby. The execution, delivery and performance by
Tatonka of this Agreement and the agreements provided for in this Agreement, and
the consummation by Tatonka of the transactions contemplated hereby and thereby
are within Tatonka's corporate powers and have been duly authorized by all
necessary action on the part of Tatonka's Board of Directors. This Agreement has
been duly executed by Tatonka. This Agreement and all other agreements and
obligations entered into and undertaken in connection with the Merger and the
transactions contemplated hereby to which Tatonka is a party constitute, or upon
execution will constitute, valid and binding agreements of Tatonka, enforceable
against it in accordance with their respective terms, except as may be limited
by bankruptcy or other laws affecting creditors' rights generally, or by general
equity principles, or by public policy.
Section 4.3. Governmental Authorization. Other than complying with the
provisions of the applicable state corporate laws regarding the approval of the
Merger and the filing of the Articles of Merger and any other required documents
related to the Merger, and other than consents, filings or notifications
required to be made or obtained solely by the Company, the execution, delivery
and performance by Tatonka of this Agreement and the agreements provided for in
this Agreement, and the consummation of the Merger and the transactions
contemplated hereby and thereby by Tatonka requires no action by or in respect
of, or filing with, any governmental body, agency, official or authority.
Section 4.4. Capitalization. The authorized capital stock of Tatonka
consists of 50,000,000 shares of Tatonka Common Stock, of which 8,515,556 shares
are issued and outstanding and 1,000,000 shares of Tatonka Preferred Stock, of
which 135,139 are outstanding. The most recent stockholder record in Tatonka's
files concerning identities and holdings of the holders of Tatonka Preferred
Stock is the "Tatonka Energy, Inc. Preferred Stock Listing" attached to this
Agreement as Exhibit C. Each outstanding share of Tatonka Common Stock has been
legally and validly issued and is fully paid and nonassessable, and was issued
pursuant to a valid exemption from registration under (i) the Securities Act of
1933, as amended, and (ii) all applicable state securities laws. Tatonka holds
25,000 shares of Tatonka Common Stock and no other shares of its capital stock
in treasury.
The Tatonka Preferred Stock was authorized by resolutions adopted and filed
by Sooner Energy Corp. (a Tatonka predecessor) with the Registrar of Companies
in British Columbia. The resolutions fixed the rights and designations of three
series of preferred stock, which rights included the non-cumulative dividend
rights, preferences upon liquidation, and rights to convert the preferred stock
into common stock. Sooner was subsequently domesticated as a Wyoming corporation
and then merged into Tatonka, which was the surviving corporation. The Oklahoma
Certificate of Merger and the Plan and Agreement of Merger provided for
conversion of the Sooner preferred stock into Tatonka Preferred Stock, but did
not set forth the rights and preferences of the Tatonka Preferred Stock and no
subsequent amendment to the Tatonka Certificate of Incorporation has done so.
Thus, the rights and preferences of the Tatonka Preferred Stock cannot be
determined conclusively. Tatonka believes that an Oklahoma court having
jurisdiction over the matter would determine that the best evidence of those
rights and preferences is the resolutions fixing the rights and
26
<PAGE>
preferences of the original preferred stock as authorized and originally issued
in British Columbia. Based in part on the foregoing, Tatonka further believes
that each of the 135,139 shares of Tatonka Preferred Stock currently outstanding
is convertible at the option of the holder thereof into 6.6667 shares of Tatonka
Common Stock and, accordingly, that the 135,139 shares of Tatonka Preferred
Stock would be convertible into an aggregate of 900,931 shares of Tatonka Common
Stock, as presently constituted. Tatonka has delivered copies of the relevant
British Columbia, Wyoming and Oklahoma documents to the Company.
No shares of capital stock of Tatonka have been issued or disposed of in
violation of the preemptive rights, rights of first refusal or similar rights of
any stockholders of Tatonka. Except for the preferred stock which is convertible
into shares of Tatonka Common Stock, Tatonka has no bonds, debentures, notes or
other obligations the holders of which have the right to vote (or are
convertible into or exercisable for securities having the right to vote) with
the stockholders of Tatonka on any matter. There exist no options, warrants,
subscriptions, calls, commitments or other rights to purchase, or securities
convertible into or exchangeable for, any of the authorized or outstanding
securities of Tatonka and no option, warrant, subscription, call, or commitment
or commission right of any kind exists which obligates Tatonka to issue any of
its authorized but unissued capital stock, except for options that are to be
issued to George C. Barker, Joe Foor and Joe R. Love following the Effective
Time. Tatonka has no obligation (contingent or otherwise) to purchase, redeem or
otherwise acquire any of its equity securities or any interests therein or to
pay any dividend or make any distribution in respect thereof.
Section 4.5. Absence of Conflicting Agreements or Required Consents. The
execution, delivery and performance of this Agreement by Tatonka and any other
documents contemplated hereby (with or without the giving of notice, the lapse
of time, or both): (i) does not require the consent of any governmental or
regulatory body or authority or any other third party except for such consents,
for which the failure to obtain would not result in a Material Adverse Effect on
Tatonka; (ii) will not conflict with any provision of Tatonka's certificate of
incorporation or bylaws; (iii) will not conflict with, result in a violation of,
or constitute a default under any law, ordinance, regulation, ruling, judgment,
order or injunction of any court or governmental instrumentality to which
Tatonka is a party or by which Tatonka or its properties are subject or bound;
(iv) will not conflict with, constitute grounds for termination of, result in a
breach of, constitute a default under, require any notice under, or accelerate
or permit the acceleration of any performance required by the terms of any
agreement, instrument, license or permit, material to this transaction, to which
Tatonka is a party or by which Tatonka or any of its properties are bound except
for such conflict, termination, breach or default, the occurrence of which would
not result in a Material Adverse Effect on Tatonka; and (v) will not create any
Encumbrance or restriction upon Tatonka Common Stock or any of the assets or
properties of Tatonka. The financial statements of Tatonka contained in the Form
10-K for the year ended December 31, 1996, and in the Form 10-Qs for the periods
subsequent thereto (a) have been prepared in accordance with generally accepted
accounting principles consistently applied (except as may be indicated therein
or in the notes thereto), (b) present fairly the financial position of Tatonka
and Tatonka Subsidiaries as of the dates indicated and present fairly the
results of Tatonka's and Tatonka
27
<PAGE>
Subsidiaries' operations for the periods then ended, and (c) are in accordance
with the books and records of Tatonka and Tatonka Subsidiaries, which have been
properly maintained and are complete and correct in all material respects.
Section 4.6. Absence of Changes. Except as permitted or contemplated by
this Agreement, since September 30, 1997, there has not been (i) any change in
the working capital, condition (financial or otherwise), assets, liabilities,
reserves, business or operations of Tatonka that has had or is reasonably likely
to have a Material Adverse Effect on Tatonka; or (ii) any declaration, setting
aside or payment of any dividend or other distribution (whether in cash, stock
or property) with respect to the Tatonka Common Stock.
Section 4.7. No Undisclosed Liabilities. Except as reflected or reserved
for in Tatonka's Current Balance Sheet, Tatonka does not have any material
liability or obligation accrued, contingent or otherwise, that is reasonably
likely to have a Material Adverse Effect on Tatonka.
Section 4.8. Litigation and Claims. There are no claims, lawsuits, actions,
arbitrations, administrative or other proceedings, governmental investigations
or inquiries pending or, to the knowledge of Tatonka, threatened against, or
affecting Tatonka. There are no unsatisfied judgments against Tatonka or any
consent decrees to which Tatonka is subject. Each of the matters, if any, set
forth in the Disclosure Schedules are fully covered by policies of insurance of
Tatonka as in effect on that date.
Section 4.9. No Violation of Law. Tatonka has not been, nor shall be as of
the Effective Time (by virtue of any action, omission to act, contract to which
it is a party or any occurrence or state of facts whatsoever), in violation of
any applicable local, state or Federal law, ordinance, regulation, order,
injunction or decree, or any other requirement of any governmental body, agency
or authority or court binding on it, or relating to its property or business or
its advertising, sales or pricing practices, except for violations which are not
reasonably likely, individually or in the aggregate, to have a Material Adverse
Effect on Tatonka.
Section 4.10. Employee Matters. Except as set forth in the Disclosure
Schedules, Tatonka does not have any material arrangements, agreements or plans
with any person with respect to the employment by Tatonka of such person or
whereby such person is to serve as an officer or director of Tatonka.
Section 4.11. Taxes.
(a) Filing of Tax Returns. Tatonka has duly and timely filed (in
accordance with any extensions duly granted by the appropriate governmental
agency, if applicable) with the appropriate governmental agencies all Tax
Returns and reports required to be filed with the United States or any state or
any political subdivision thereof or any foreign jurisdiction. All such Tax
Returns or reports are complete and accurate in all material respects and
properly reflect the taxes of Tatonka for the periods covered thereby.
(b) Payment of Taxes. Except for such items as Tatonka may be
disputing in good faith by proceedings in compliance with applicable law, which
are described in Schedule
28
<PAGE>
4.11(b), (i) Tatonka has paid all taxes, penalties, assessments and interest
that have become due with respect to any Tax Returns that it has filed and has
properly accrued on its books and records for all of the same that have not yet
become due and (ii) Tatonka is not delinquent in the payment of any tax,
assessment or governmental charge.
(c) No Pending Deficiencies, Delinquencies, Assessments or Audits.
Tatonka has not received any notice that any tax deficiency or delinquency has
been asserted against Tatonka. There is no unpaid assessment, proposal for
additional taxes, deficiency or delinquency in the payment of any of the taxes
of Tatonka that could be asserted by any taxing authority. There is no taxing
authority audit of Tatonka pending, or to the knowledge of Tatonka, threatened,
and the results of any completed audits are properly reflected in the financial
statements of Tatonka. To the best of its knowledge, Tatonka has not violated
any Federal, state, local or foreign tax law.
(d) No Extension of Limitation Period. Tatonka has not granted an
extension to any taxing authority of the limitation period during which any tax
liability may be assessed or collected.
(e) All Withholding Requirements Satisfied. All monies required to
be withheld by Tatonka and paid to governmental agencies for all income, social
security, unemployment insurance, sales, excise, use, and other taxes have been
collected or withheld and paid to the respective governmental agencies.
(f) Foreign Person. Neither Tatonka nor any holders of Tatonka
Common Stock is a foreign person, as such term is referred to in Section
1445(f)(3) of the Code.
(g) Tax Exempt Entity. None of the assets of Tatonka are subject to
a lease to a "tax exempt entity" as such term is defined in Section 168(h)(2) of
the Code.
(h) Collapsible Corporation. Tatonka has not at any time consented,
and the holders of Tatonka Common Stock will not permit Tatonka to elect, to
have the provisions of Section 341(f)(2) of the Code apply to it.
(i) Boycotts. Tatonka has not at any time participated in or
cooperated with any international boycott as defined in Section 999 of the Code.
(j) Parachute Payments. No payment required or contemplated to be
made by Tatonka will be characterized as an "excess parachute payment" within
the meaning of Section 280G(b)(1) of the Code.
(k) S Corporation. Tatonka has not made an election to be taxed as
an "S" corporation under Section 1362(a) of the Code.
(l) Personal Holding Companies. Tatonka is not or has not been a
personal holding company within the meaning of Section 542 of the Code.
Section 4.12. Related Party Arrangements. Schedule 4.12 sets forth a
description of any interest held, directly or indirectly, by any officer,
director or other Affiliate of Tatonka in any property, real or personal or
mixed, tangible or intangible, used in or pertaining to Tatonka's business and
any arrangement or agreement with any such person concerning the
29
<PAGE>
provision of goods or services or other matters pertaining to Tatonka's
business.
Section 4.13. Statements True and Correct. No representation or warranty
made in this Agreement by Tatonka, nor any statement, certificate, information,
exhibit or instrument to be furnished by Tatonka to the Company or a Stockholder
pursuant to this Agreement, contains or will contain as of the Effective Time
any untrue statement of material fact or omits or will omit to state a material
fact necessary to make the statements contained herein and therein not
misleading.
Section 4.14. Disclosure Schedules. All Disclosure Schedules required by
Article IV hereof and attached hereto are true, correct and complete in all
material respects as of the date of this Agreement.
Section 4.15. Finder's Fees. No investment banker, broker, finder or other
intermediary has been retained by or is authorized to act on behalf of Tatonka
who is entitled to any fee or commission upon consummation of the transactions
contemplated by this Agreement or referred to herein.
ARTICLE V
CLOSING DATE REPRESENTATIONS AND WARRANTIES REGARDING TATONKA SUB
Tatonka and Tatonka Sub, jointly and severally, represent and warrant that
the following will be true and correct on the Closing Date as if made on that
date:
Section 5.1. Authorization and Validity. The execution, delivery and
performance by Tatonka Sub of this Agreement and the consummation of the
transactions contemplated thereby, have been duly authorized by Tatonka Sub.
This Agreement will be as of the Closing Date duly executed and delivered by
Tatonka Sub and will constitute the legal, valid and binding obligation of
Tatonka Sub enforceable against Tatonka Sub in accordance with its respective
terms, except as may be limited by bankruptcy or other laws affecting creditors'
rights generally, or by equity principles, or by public policy.
Section 5.2. No Violation. Neither the execution, delivery or performance
of this Agreement nor the consummation of the transactions contemplated hereby
will conflict with, or result in a violation or breach of the terms, conditions
or provisions of, or constitute a default under, the certificate of
incorporation or bylaws of Tatonka Sub.
Section 5.3. No Business, Agreements, Assets or Liabilities. Tatonka Sub
has not commenced business since its incorporation. Tatonka Sub does not own any
assets (tangible or intangible) other than the consideration received upon the
issuance of shares of its capital stock and Tatonka Sub does not have any
liabilities, accrued, contingent or otherwise (known or unknown and asserted or
unasserted) other than those assumed pursuant to this Agreement.
ARTICLE VI
COVENANTS OF THE COMPANY
The Company makes the covenants and agreements as set forth in this Article
VI,
30
<PAGE>
which shall apply with respect to the period from this date to the Effective
Time and, to the extent contemplated in this Agreement, thereafter and agree
that:
Section 6.1. Conduct of the Company. From the date hereof until the
Effective Time, the Company shall, in all material respects, conduct its
business in the ordinary and usual course consistent with past practices and
shall use reasonable efforts to:
(a) preserve intact its business and its relationships with Payors,
referral sources, customers, suppliers, patients, employees and others having
business relations with it;
(b) maintain and keep its properties and assets in good repair and
condition consistent with past practice as is material to the conduct of the
business of the Company;
(c) continuously maintain insurance coverage substantially
equivalent to the insurance coverage in existence on the date hereof. In
addition, without the written consent of Tatonka, the Company shall not:
(1) amend its articles or certificate of incorporation or bylaws, or
other charter documents;
(2) issue, sell or authorize for issuance or sale, shares of any
class of its securities (including, but not limited to, by way of stock
split, dividend, recapitalization or other reclassification) or any
subscriptions, options, warrants, rights or convertible securities, or
enter into any agreements or commitments of any character obligating it to
issue or sell any such securities;
(3) redeem, purchase or otherwise acquire, directly or indirectly,
any shares of its capital stock or any option, warrant or other right to
purchase or acquire any such shares;
(4) declare or pay any dividend or other distribution (whether in
cash, stock or other property) with respect to its capital stock (except as
expressly contemplated in this Agreement);
(5) voluntarily sell, transfer, surrender, abandon or dispose of any
of its assets or property rights (tangible or intangible) other than the
sale of inventory, if any, in the ordinary course of business consistent
with past practices;
(6) grant or make any mortgage or pledge or subject itself or any of
its properties or assets to any lien, charge or encumbrance of any kind,
except liens for taxes not currently due and except for liens which arise
by operation of law;
(7) voluntarily incur or assume any liability or indebtedness
(contingent or otherwise), except in the ordinary course of business or
which is reasonably necessary for the conduct of its business;
(8) make or commit to make any capital expenditures which are not
reasonably necessary for the conduct of its business;
(9) grant any increase in the compensation payable or to become
payable to directors, officers, consultants or employees other than merit
increases to employees of the Company who are not directors or officers of
the Company, except in the ordinary
31
<PAGE>
course of business and consistent with past practices;
(10) change in any manner any accounting principles or methods other
than changes which are consistent with generally accepted accounting
principles;
(11) enter into any material commitment or transaction other than in
the ordinary course of business;
(12) take any action which could reasonably be expected to have a
Material Adverse Effect on the Company;
(13) apply any of its assets to the direct or indirect payment,
discharge, satisfaction or reduction of any amount payable directly or
indirectly to or for the benefit of any Affiliate of the Company, other
than in the ordinary course and consistent with past practices;
(14) agree, whether in writing or otherwise, to do any of the
foregoing; and
(15) take any action at the Board of Director or Stockholder level
to (in any way) amend, revise or otherwise affect the prior corporate
approval and effectiveness of this Agreement or any of the agreements
attached as exhibits hereto, other than as required to discharge its or
their fiduciary duties.
Section 6.2. Title to Assets; Indebtedness. As of the Effective Time, the
Company shall (i) except for sales of assets held as inventory, if any, in the
ordinary course of business prior to the Effective Time and except as otherwise
specifically described in the Disclosure Schedules to this Agreement, have good
and valid title to all of its assets free and clear of all Encumbrances of any
nature whatsoever, except for current year ad valorem taxes and liens which
arise by operation of law, and (ii) have no direct or indirect indebtedness
except for indebtedness disclosed in the Company Financial Statements, the
Disclosure Schedules hereto or for normal and recurring accrued obligations of
the Company arising in connection with its business operations in the ordinary
course of business and which arise from the purchase of merchandise, supplies,
inventory and services used in connection with the provision of services.
Section 6.3. Access. At all times prior to the Effective Time, Tatonka's
employees, attorneys, accountants, agents and other authorized and designated
representatives will be allowed full access upon reasonable prior notice and
during regular business hours (and at such other times as the parties may
reasonably agree) to the properties, books and records of the Company,
including, without limitation, deeds, title documents, leases, patient lists,
insurance policies, minute books, share certificate books, share registers,
accounts, tax returns, financial statements and all other data that, in the
reasonable opinion of Tatonka, are required for Tatonka to make such
investigation as it may desire of the properties and business of the Company.
Tatonka shall also be allowed full access upon reasonable prior notice and
during regular business hours (and at such other times as the parties may
reasonably agree) to consult with the officers, employees (after announcement by
the Company of the Merger to its employees which shall occur no later than three
days subsequent to execution hereof by the Company), accountants, counsel and
agents of the
32
<PAGE>
Company in connection with such investigation of the properties and business of
the Company. No investigation by Tatonka shall diminish or otherwise affect any
of the representations, warranties, covenants or agreements of the Company under
this Agreement. Any access or investigation referred to in this Section 6.3
shall be conducted in such a manner as to minimize the disruption to the
Company's ongoing business operations.
Section 6.4. Acquisition Proposals. The Company shall not, and shall cause
each of its directors, officers, employees or agents not to directly or
indirectly:
(a) solicit, initiate, encourage or participate in any negotiations
or discussions with respect to any offer or proposal to acquire all or a
substantial portion of the business, properties or capital stock of the Company,
whether by merger, consolidation, share exchange, business combination, purchase
of assets or otherwise; or
(b) except as required by law or pursuant to subpoena or court
order, disclose to any Person, other than Tatonka or its agents, any information
not customarily disclosed concerning the business, assets, liabilities,
properties and personnel of the Company, or, without Tatonka's prior written
approval, afford to any Person other than Tatonka and its agents access to the
properties, books or records of the Company. If the Company receives any offer
or proposal after the date hereof, written or otherwise, of the type referred to
above, the Company shall promptly inform Tatonka of such offer or proposal,
decline such offer and furnish Tatonka with a copy thereof if such offer or
proposal is in writing.
Section 6.5. Compliance With Obligations. Prior to the Effective Time, the
Company shall comply in all material respects with (i) all applicable Federal,
state, local and foreign laws, rules and regulations; (ii) all material
agreements and obligations, including its articles or certificate of
incorporation or charter documents, by which it or its properties or its assets
(real, personal or mixed, tangible or intangible) may be bound; and (iii) all
decrees, orders, writs, injunctions, judgments, statutes, rules and regulations
applicable to the Company, and its respective properties or assets.
Section 6.6. Notice of Certain Events. The Company shall promptly notify
Tatonka of:
(a) any notice or other communication from any Person or entity
alleging that the consent of such Person or entity is or may be required in
connection with the transactions contemplated by this Agreement;
(b) any employment of any new non-hourly employee by the Company who
is expected to receive annualized compensation of at least $50,000 in 1998;
(c) any termination of employment by, or threat to terminate
employment received from, any salaried or non-hourly, skilled employee of the
Company;
(d) any notice or other communication from any governmental or
regulatory agency or authority in connection with the transactions contemplated
by this Agreement;
(e) any actions, suits, claims, investigations or proceedings
commenced or threatened against, relating to or involving or otherwise affecting
the Company which, if
33
<PAGE>
pending on the date of this Agreement, would have been required to have been
disclosed to Tatonka hereunder or which relate to the consummation of the
transactions contemplated by this Agreement;
(f) any material adverse change in the operation of the Company,
including but not limited to any licensure or certification deficiencies, or
violations; limitations on a license or a provider agreement; freeze or
reduction in Medicare or Medicaid rates, notice of overpayment; being the
subject of any investigation relating to patient abuse, fraud, kickbacks, false
claims or other alleged illegal payment practices under the Fraud and Abuse
Statutes; and
(g) any notice or other communication indicating a material
deterioration in the relationship with any Payor or supplier or key employee of
the Company and, if requested by Tatonka, will exert its reasonable best efforts
to restore the relationship.
Section 6.7. Stockholders' Consent. The Company shall obtain the unanimous
approval of the Stockholders to the Merger. In obtaining the approval of the
Stockholders, the Company shall provide each Stockholder with such information
as may be required by applicable law or as Tatonka shall deem appropriate. The
Board of Directors of the Company shall recommend the approval of the Merger by
the Stockholders of the Company.
Section 6.8. Obligations of Company and Stockholders. The Stockholders will
take all action reasonably necessary to cause the Company to perform its
obligations under this Agreement and all related agreements and to consummate
the Merger and other transactions contemplated hereby and thereby on the terms
and conditions set forth in this Agreement and such agreements; provided,
however, that this covenant shall not require the Company to make any
expenditures that are not expressly set forth in this Agreement or otherwise
contemplated in this Agreement.
Section 6.9. Accounting and Tax Matters. The Company will not change in any
material respect the accounting methods or practices followed by the Company
(including any material change in any assumption underlying, or any method of
calculating, any bad debt, contingency or other reserve), except as may be
required by generally accepted accounting principles. The Company will not make
any material tax election except in the ordinary course of business consistent
with past practice, change any material tax election already made, adopt any tax
accounting method except in the ordinary course of business consistent with past
practice, change any tax accounting method, enter into any closing agreement,
settle any tax claim or assessment or consent to any tax claim or assessment or
any waiver of the statute of limitations for any such claim or assessment. The
Company will duly, accurately and timely (without regard to any extensions of
time) file all returns, information statements and other documents relating to
taxes of the Company required to be filed by it, and pay all taxes required to
be paid by it, on or before the Closing Date.
ARTICLE VII
COVENANTS OF TATONKA AND TATONKA SUB
Tatonka and Tatonka Sub agrees that between the date hereof and the
Closing:
34
<PAGE>
Section 7.1. Consummation of Agreement. Tatonka and Tatonka Sub will take
all action reasonably necessary to cause the consummation of the transactions
contemplated hereby in accordance with their terms and conditions and take all
corporate and other action necessary to approve the Merger; provided, however,
that this covenant shall not require Tatonka and Tatonka Sub to make any
expenditures that are not expressly set forth in this Agreement or otherwise
contemplated in this Agreement.
Section 7.2. Requirements to Effect the Merger and Acquisitions. Tatonka
and Tatonka Sub will use its best efforts to take, or cause to be taken, all
actions necessary to effect the Merger under applicable law, including without
limitation the filing with the appropriate government officials of all necessary
documents in form approved by counsel for the parties to this Agreement.
Section 7.3. Access. Tatonka and Tatonka Sub shall, at reasonable times
during normal business hours and on reasonable notice, permit the Company and
its authorized representatives of the Company reasonable access to, and make
available for inspection, all of the assets and business of Tatonka and Tatonka
Sub, including its executive officers, and permit the Company and its authorized
representatives to inspect and, at the Company's sole expense, make copies of
all documents, records and information with respect to the affairs of Tatonka
and Tatonka Sub as the Company and its representatives may reasonably request,
all for the sole purpose of permitting the Company to become familiar with the
business and assets and liabilities of Tatonka and Tatonka Sub. No investigation
by the Company or the Stockholders shall diminish or otherwise affect any of the
representations, warranties, covenants or agreements of Tatonka under this
Agreement.
Section 7.4. Notification of Certain Matters. Tatonka and Tatonka Sub shall
promptly inform the Company in writing of (a) any notice of, or other
communication relating to, a default or event that, with notice or lapse of time
or both, would become a default, received by Tatonka subsequent to the date of
this Agreement and prior to the Effective Time under any contract, agreement or
investment material to Tatonka' and Tatonka Sub's condition (financial or
otherwise), operations, assets, liabilities or business and to which it is
subject; or (b) any material adverse change in Tatonka's condition (financial or
otherwise), operations, assets, liabilities or business.
ARTICLE VIII
COVENANTS OF TATONKA, TATONKA SUB AND THE COMPANY
Tatonka, Tatonka Sub and the Company agree as follows:
Section 8.1. Filings; Other Action.
(a) The Company shall cooperate with Tatonka and Tatonka Sub in the
preparation of any and all documents required pursuant to the transactions
contemplated by this Agreement, including documents required to be filed under
Federal or state securities laws. The Company shall furnish all information
concerning the Company as may be reasonably requested in connection with any
such action in a timely manner.
35
<PAGE>
(b) The Company, Tatonka and Tatonka Sub each separately represent
and warrant that (i) in the case of the Company, none of the written information
or documents supplied or to be supplied by it specifically for inclusion in any
1934 Act filing, by exhibit or otherwise and (ii) in the case of Tatonka will,
at the time any 1934 Act filing and each amendment and supplement thereto, is
made, none of them contain any untrue statement of a material fact or omit to
state any material fact required to be stated therein or necessary to make the
statements therein, in the light of the circumstances under which they were
made, not misleading. The Company shall be entitled to review each 1934 Act
filing and each of the amendments thereto, if any, prior to its filing. The
Company's review of the 1934 Act filings shall not diminish or otherwise affect
the representations, covenants and warranties of Tatonka and Tatonka Sub
contained in this Agreement.
(c) The Company shall, upon request, furnish Tatonka with all
information concerning itself, its subsidiaries, directors, officers, partners
and Stockholders, and such other matters as may be reasonably requested by
Tatonka in connection with the preparation of the 1934 Act filings and each of
the amendments or supplements thereto, or any other statement, filing, notice or
application made by or on behalf of each such party or any of its subsidiaries
to any governmental entity in connection with the Merger and the other
transactions contemplated by this Agreement.
Section 8.2. Amendments of Disclosure Schedules. Each party hereto agrees
that, with respect to the representations and warranties of such party contained
in this Agreement, such party shall have the continuing obligation until the
Closing to supplement or amend promptly the Disclosure Schedules with respect to
any matter that would have been or would be required to be set forth or
described in the Disclosure Schedules in order to not materially breach any
representation, warranty or covenant of such party contained in this Agreement;
provided that no amendment or supplement to a Disclosure Schedule that
constitutes or reflects a Material Adverse Effect on the Company may be made
unless Tatonka consents to such amendment or supplement, and no amendment or
supplement to a Disclosure Schedule that constitutes or reflects a Material
Adverse Effect on Tatonka may be made unless the Company consents to such
amendment or supplement. For purposes of this Agreement, including without
limitation for purposes of determining whether the conditions set forth in
Sections 9.1 and 10.1 have been fulfilled, the Disclosure Schedules hereto shall
be deemed to be the Disclosure Schedules as amended or supplemented pursuant to
this Section 8.2. In the event that the Company seeks to amend or supplement a
Disclosure Schedule pursuant to this Section 8.2 and Tatonka does not consent to
such amendment or supplement, or Tatonka seeks to amend or supplement a
Disclosure Schedule pursuant to this Section 8.2, and the Company does not
consent, this Agreement shall be deemed terminated by mutual consent as set
forth in Section 14.1(a) hereof.
Section 8.3. Actions Contrary to Stated Intent. No party hereto will
knowingly, either before or after the Merger, take any action that would prevent
the Merger from qualifying as a tax-free merger within the meaning of Section
368 of the Code.
Section 8.4. Public Announcements. The parties hereto will consult with
each other before issuing any press release or making any public statement with
respect to this
36
<PAGE>
Agreement and the transactions contemplated hereby and, except as may be
required by applicable law, will not issue any such press release or make any
such public statement prior to such consultation, although the foregoing shall
not apply to any disclosure by Tatonka in any filing with the SEC.
Section 8.5. Expenses. Each party to this Agreement shall be solely
responsible for their own fees and expenses with respect to the transactions
contemplated in this Agreement including, without limitation, the fees charged
by attorneys, accountants and financial advisors retained by such parties. The
fees and expenses incurred by the Company shall be paid by the Company in full
immediately prior to the Closing and such expenses shall be the sole
responsibility of the Stockholders following the Closing Date and not Tatonka.
Section 8.6. Patient Confidentiality. Tatonka shall agree to keep all
records and information regarding the patients of the Company confidential in
accordance with all applicable laws.
Section 8.7. 1934 Act Filings. Tatonka shall prepare and file a Form 8-K
regarding the transactions covered by this Agreement and take any action
required to be taken under the applicable state Blue Sky or other securities
laws in connection with the issuance of the shares of Tatonka Common Stock upon
consummation of the Merger.
ARTICLE IX
CONDITIONS PRECEDENT OF TATONKA AND TATONKA SUB
Except as may be waived in writing by Tatonka, the obligations of Tatonka
and Tatonka Sub hereunder are subject to the fulfillment at or prior to the
Effective Time of each of the following conditions:
Section 9.1. Representations and Warranties. The representations and
warranties of the Company contained in this Agreement and each Stockholder
contained in the Stockholders Representation Letter (as delivered pursuant to
Section 9.7 hereof) shall have been true and correct in all material respects
when initially made and shall be true and correct in all material respects as of
the Effective Time.
Section 9.2. Covenants. The Company shall have performed and complied in
all material respects with all covenants required by this Agreement to be
performed and complied with by the Company prior to the Effective Time.
Section 9.3. Proceedings. No action, proceeding or order by any court or
governmental body or agency shall have been threatened orally or in writing,
asserted, instituted or entered to restrain or prohibit the carrying out of the
transactions contemplated hereby.
Section 9.4. No Material Adverse Effect. No Material Adverse Effect on the
Company shall have occurred since December 31, 1997, whether or not such change
shall have been caused by the deliberate act or omission of the Company or any
Stockholder.
Section 9.5. Government Approvals and Required Consents. The Company, the
37
<PAGE>
Stockholders and Tatonka shall have obtained all licenses, permits and all
necessary government and other third-party approvals and consents required under
any law, statements, rule, regulation or ordinance to consummate the
transactions contemplated by this Agreement.
Section 9.6. Closing Deliveries. Tatonka shall have received all Disclosure
Schedules, documents, assignments and agreements, duly executed and delivered in
form reasonably satisfactory to Tatonka, referred to in Section 11.1.
Section 9.7. Stockholder Representation Letter. Each Stockholder shall have
executed and delivered to Tatonka the Stockholder Representation Letter in
substantially the form of Exhibit C.
ARTICLE X
CONDITIONS PRECEDENT OF THE COMPANY
Except as may be waived in writing by the Company, the obligations of the
Company hereunder are subject to fulfillment at or prior to the Effective Time
of each of the following conditions:
Section 10.1. Representations and Warranties. The representations and
warranties of Tatonka and Tatonka Sub contained in this Agreement shall be true
and correct in all material respects when initially made and shall be true and
correct in all material respects as of the Effective Time.
Section 10.2. Covenants. Tatonka and Tatonka Sub shall have performed and
complied in all material respects with all covenants and conditions required by
this Agreement to be performed and complied with by it prior to the Effective
Time.
Section 10.3. Proceedings. No action, proceeding or order by any court or
governmental body or agency shall have been threatened in writing, asserted,
instituted or entered to restrain or prohibit the carrying out of the
transactions contemplated hereby.
Section 10.4. Government Approvals and Required Consents. The Company, the
Stockholders, Tatonka and Tatonka Sub shall have obtained all licenses, permits
and all necessary government and other third-party approvals and consents
(including the unanimous consent of the Stockholders) required under any law,
contracts or any statute, rule, regulation or ordinances to consummate the
transactions contemplated by this Agreement.
Section 10.5. Closing Deliveries. The Company shall have received all
Disclosure Schedules, documents, assignments and agreements, duly executed and
delivered in form reasonably satisfactory to the Company referred to in Section
11.2.
Section 10.6. No Material Adverse Effect. No Material Adverse Effect on
Tatonka or Tatonka Sub shall have occurred since September 30, 1997, regardless
of whether such change shall have been caused by the deliberate act or omission
of Tatonka or Tatonka Sub.
38
<PAGE>
ARTICLE XI
CLOSING DELIVERIES
Section 11.1. Deliveries of the Company. At or prior to the Effective Time,
the Company shall deliver to Tatonka the following, all of which shall be in a
form reasonably satisfactory to Tatonka:
(a) a copy of resolutions of the Board of Directors of the Company
authorizing the execution, delivery and performance of this Agreement and all
related documents and agreements and consummation of the Merger, each certified
by the Secretary of the Company as being true and correct copies of the
originals thereof subject to no modifications or amendments;
(b) a certificate of the President of the Company dated the Closing
Date, as to the truth and correctness of the representations and warranties of
the Company contained in this Agreement on and as of the Effective Time;
(c) a certificate of the President of the Company dated the Closing
Date, (i) as to the performance of and compliance in all material respects by
the Company with all covenants contained in this Agreement on and as of the
Effective Time and (ii) certifying that all conditions precedent required by the
Company to be satisfied shall have been satisfied;
(d) a certificate of the Secretary of the Company certifying as to
the incumbency of the directors and officers of such corporation and as to the
signatures of such directors and officers who have executed documents delivered
at the Closing on behalf of that corporation;
(e) certificates, dated within ten days prior to the Effective Time,
of the Secretary of State of Texas for the Company establishing that each such
corporation is in existence, has paid all franchise or similar taxes, if any,
and, if applicable, otherwise is in good standing to transact business in the
state of Texas;
(f) certificates, dated within ten days prior to the Effective Time,
of the Secretaries of State of the states in which either the Company is
qualified to do business, to the effect that each such corporation is qualified
to do business and, if applicable, is in good standing as a foreign corporation
in each of such states;
(g) all authorizations, consents, approvals, permits and licenses
referenced in Section 3.23;
(h) the resignations of the directors and officers of the Company as
requested by Tatonka;
(i) executed Articles of Merger necessary to effect the Merger
referred to in Section 2.1;
(j) such other instrument or instruments of transfer prepared by
Tatonka as shall be necessary or appropriate, as Tatonka or its counsel shall
reasonably request, to carry out and effect the purpose and intent of this
Agreement.
Section 11.2. Deliveries of Tatonka. At or prior to the Effective Time,
Tatonka shall
39
<PAGE>
deliver to the Company the following, all of which shall be in a form reasonably
satisfactory to the Company:
(a) a copy of resolutions of the Board of Directors of Tatonka
authorizing the execution, delivery and performance of this Agreement, and all
related documents and agreements, certified by Tatonka's Secretary as being true
and correct copies of the originals thereof subject to no modifications or
amendments;
(b) a copy of resolutions of the Board of Directors of Tatonka Sub
authorizing the execution, delivery and performance of this Agreement certified
by the Secretary of Tatonka Sub as being true correct copies of the originals
thereof subject to no modifications or amendments;
(c) a certificate of the President of Tatonka and Tatonka Sub dated
the Closing Date as to the truth and correctness of the representations and
warranties of Tatonka and Tatonka Sub contained in this Agreement on and as of
the Effective Time;
(d) a certificate of the President of Tatonka and Tatonka Sub dated
the Closing Date, (i) as to the performance and compliance by Tatonka or Tatonka
Sub with all covenants contained in this Agreement on and as of the Effective
Time and (ii) certifying that all conditions precedent required to be satisfied
by Tatonka and Tatonka Sub shall have been satisfied;
(e) a certificate of the Secretary of Tatonka and Tatonka Sub
certifying as to the incumbency and to the signatures of the officers of Tatonka
or Tatonka Sub who have executed documents delivered at the Closing on behalf of
Tatonka or Tatonka Sub;
(f) a certificate, dated within ten days prior to the Effective
Time, of the secretary of state of incorporation establishing that Tatonka and
Tatonka Sub are, respectively, in existence, have paid all franchise or similar
taxes, if any, and otherwise are in good standing to transact business in the
states of Oklahoma and Texas;
(g) certificates (or photocopies thereof), dated within ten days
prior to the Effective Time, of the Secretaries of State of the states in which
either Tatonka and Tatonka Sub is qualified to do business, to the effect that
Tatonka and Tatonka Sub is qualified to do business and is in good standing as a
foreign corporation in such state;
(h) executed Articles of Merger necessary to effect the Merger
referred to in Section 2.1;
(i) the Merger Consideration in accordance with Article II and
Exhibit A hereof; and
(j)such other instrument or instruments of transfer prepared by the
Company as shall be necessary or appropriate, as the Company or its counsel
shall reasonably request, to carry out and effect the purpose and intent of this
Agreement.
ARTICLE XII
POST CLOSING MATTERS
Section 12.1. Further Instruments of Transfer. Following the Closing, at
the request
40
<PAGE>
of Tatonka or the Surviving Corporation and at Tatonka's sole cost and expense,
the Stockholders and the Company shall deliver any further instruments of
transfer and take all reasonable action as may be necessary or appropriate to
carry out the purpose and intent of this Agreement. Following the Closing,
Tatonka or the Surviving Corporation shall deliver any further instruments of
transfer and take all reasonable action as may be necessary and appropriate to
carry out the purpose and intent of this Agreement.
Section 12.2. Merger Tax Covenant.
(a) The parties intend that the Merger will qualify as a tax-free
merger within the meaning of Section 368 of the Code in which the Company will
not recognize gain or loss, and pursuant to which any gain recognized by a
Stockholder as a result of the Merger will not exceed the amount of any cash
received by a Stockholder in the Merger (a "Reorganization").
(b) Both prior to and after the Effective Time, all books and
records shall be maintained, and all Tax Returns and schedules thereto shall be
filed in a manner consistent with the Merger being treated as a Reorganization.
These obligations are excused as to a party required to maintain the books or
file a Tax Return if such party has provided to the other parties a written
opinion of competent tax counsel to the effect that there is not substantial
authority, within the meaning of Section 6662(d)(2)(B)(i) of the Code, to report
the Merger as a Reorganization and such opinion either is furnished prior to the
Effective Time or is based on facts or events not known at the Effective Time.
Each party shall provide to each other party such tax information, reports,
returns, or schedules as may be reasonably required to assist such party in
accounting for and reporting the Merger as a Reorganization.
(c) The parties agree that no Stockholder shall be liable for any
taxes incurred by the Company and for which Tatonka has successor liability
therefor which arise solely as a result of the Merger or the consummation of the
transactions contemplated hereby; provided that the foregoing shall not limit or
otherwise be deemed a waiver of any right of indemnification under Section 13.1
for a breach of any representation, warranty or covenant of the Company or any
Stockholder.
Section 12.3. Current Public Information. Tatonka shall use its best
efforts to cause the requirements of Rule 144(c) under the Securities Act to be
met with respect to Tatonka for so long as those requirements must be met to
enable sales by the Stockholders who are affiliates of the Company to meet the
requirements of Rule 145(d) under the Securities Act.
Section 12.4. Change of Tatonka Name. Tatonka shall use its best efforts to
cause Tatonka's name to be changed to "PHYMED, INC.", or such other name as the
Board of Directors of Tatonka, in consultation with the Stockholders, shall
choose, to reflect better the nature of Tatonka's business and operations
following consummation of the transactions contemplated hereby.
ARTICLE XIII
REMEDIES
Section 13.1. Indemnification by the Company and the Stockholders. Subject
to the
41
<PAGE>
terms and conditions of this Article XIII, the Company and the Stockholders
agree to indemnify, defend and hold Tatonka and the Surviving Corporation and
their respective directors, officers, stockholders, employees, agents,
attorneys, consultants and Affiliates harmless from and against all losses,
claims, obligations, demands, assessments, penalties, liabilities, costs,
damages, reasonable attorneys' fees and expenses (including, without limitation,
all costs of experts and all costs incidental to or in connection with any
appellate process) (collectively, "Damages") asserted against or incurred by
such individuals and/or entities arising out of or resulting from:
(a) a breach by the Company or any Stockholder of any representation
or warranty or covenant of the Company or any Stockholder contained in this
Agreement or in any Disclosure Schedule or certificate delivered thereunder;
(b) any violation (or alleged violation) by the Company and/or any
of its past or present directors, officers, partners, Stockholders, employees
(including, without limitation, any Physician Employee), agents, attorneys,
consultants and Affiliates of any state or Federal law governing health care
fraud and abuse or prohibition on referral of patients to Persons in which a
licensed professional has a financial or other form of interest (including, but
not limited to, fraud and abuse in the Medicare and Medicaid Programs) occurring
on or before the Closing Date, or any overpayment or obligation (or alleged
overpayment or obligation) arising out of or resulting from claims submitted to
any Payor on or before the Closing Date; and
(c) any liability under the Securities Act, the Exchange Act or any
other Federal or state "blue sky" or securities law or regulation, at common law
or otherwise, arising out of or based upon any untrue statement of material fact
in any 1934 Act filing, or any amendment thereof or supplement thereto relating
to the Company (including any Company Subsidiary) or failure to state
information necessary to make the statements required to be stated therein not
misleading arising solely from information provided in writing to Tatonka or its
counsel by the Company or any Stockholder or their agents specifically for
inclusion in any such 1934 Act filing, or any amendment thereof or supplement
thereto.
Nothing contained in this Agreement shall relieve the Company of any
liability or limit any liability that it may have in the case of fraud in
connection with the transactions contemplated by this Agreement.
Section 13.2. Indemnification by Tatonka and Tatonka Sub. Subject to the
terms and conditions of this Article XIII, Tatonka and Tatonka Sub hereby agree
to indemnify, defend and hold the Stockholders, the Company and its directors,
officers, stockholders, employees, agents, attorneys, consultants and Affiliates
harmless from and against all Damages asserted against or incurred by such
individuals and/or entities arising out of or resulting from:
(a) a breach by Tatonka or Tatonka Sub of any representation or
warranty (without giving effect to any Material Adverse Effect qualifier
contained as part of any such representation or warranty) or covenant of Tatonka
or Tatonka Sub contained in this Agreement or in any schedule or certificate
delivered hereunder; and
(b) any liability under the Securities Act, the Exchange Act or any
other Federal or
42
<PAGE>
state "blue sky" or securities law or regulation, at common law or otherwise,
arising out of or based upon any untrue statements of material fact in any 1934
Act filing, or any amendment thereof or supplement thereto, or required to be
stated therein or failure to state information necessary to make the statements
therein not misleading (except for any liability based upon any actual or
alleged untrue statement of material fact or an omission to state a material
fact relating the Company or any Stockholder which was derived from any
information provided in writing by the Company or a Company Subsidiary or any of
their agents contained in the representations and warranties set forth in this
Agreement or any certificate, exhibit, schedule or instrument required to be
delivered under this Agreement).
Nothing contained in this Agreement shall relieve Tatonka of any liability
or limit any liability that it may have in the case of fraud in connection with
the transactions contemplated by this Agreement.
Section 13.3. Conditions of Indemnification. All claims for indemnification
under this Agreement shall be asserted and resolved as follows:
(a) Any party claiming indemnification under the Agreement (an
"Indemnified Party") shall promptly (and, in the event, at least ten days prior
to the due date for any responsive pleadings, filings or other documents) (i)
notify the party for whom indemnification is sought (the "Indemnifying Party) of
any third-party claim or claims asserted against the Indemnified Party ("Third
Party Claim") that could give rise to a right of indemnification under this
Agreement and (ii) transmit to the Indemnifying Party a written notice ("Claim
Notice") describing in reasonable detail the nature of the Third Party Claim, a
copy of all papers served with respect to such claim (if any), an estimate of
the amount of Damages attributable to the Third Party Claim and the basis of the
Indemnified Party's request for indemnification under this Agreement. The
failure to promptly deliver a Claim Notice shall not relieve any Indemnifying
Party of its obligations to any Indemnified Party with respect to the related
Third Party Claim except to the extent that the resulting delay is materially
prejudicial to the defense of such claim. Within 30 days after receipt of any
Claim Notice (the "Election Period"), the Indemnifying Party shall notify the
Indemnified Party (x) whether the Indemnifying Party disputes its potential
liability to the Indemnified Party under this Article XIII with respect to such
Third Party Claim and (y) whether the Indemnifying Party desires, at the sole
cost and expense of such Indemnifying Party, to defend the Indemnified Party
against such Third Party Claim.
(b) If the Indemnifying Party notifies the Indemnified Party within
the Election Period that the Indemnifying Party elects to assume the defense of
the Third Party Claim, then the Indemnifying Party shall have the right to
defend, at their sole cost and expense, with counsel reasonably acceptable to
such Indemnified Party, such Third Party Claim by all appropriate proceedings,
which proceedings shall be prosecuted diligently by the Indemnifying Party to a
final conclusion or settled at the discretion of the Indemnifying Party in
accordance with this Section 13.3(b). Except as set forth in Section 13.3(f)
below, the Indemnifying Party shall have full control of such defense and
proceedings, including any compromise or settlement thereof. The Indemnified
Party is hereby authorized, at the sole cost and expense of the Indemnifying
Party (but only if the Indemnified Party is entitled to indemnification
43
<PAGE>
hereunder), to file, during the Election Period, any motion, answer or other
pleadings that the Indemnified Party shall deem necessary or appropriate to
protect its interests or those of the Indemnifying Party and not prejudicial to
the Indemnifying Party. If requested by the Indemnifying Party, the Indemnified
Party agrees, at the sole cost and expense of the Indemnifying Party, to
cooperate with the Indemnifying Party and their counsel in contesting any Third
Party Claim that the Indemnifying Party elects to contest, including, without
limitation, the making of any related counterclaim against the person asserting
the Third Party Claim or any cross-complaint against any person. The Indemnified
Party may participate in, but not control, any defense or settlement of any
Third Party Claim controlled by the Indemnifying Party pursuant to this Section
13.3(b) and shall bear its own costs and expenses with respect to such
participation; provided, however, that if the named parties to any such action
(including any impleaded parties) include both the Indemnifying Party and the
Indemnified Party, and the Indemnified Party has been advised by counsel that
there may be one or more legal defenses available to it that are different from
or additional to those available to the Indemnifying Party, then the Indemnified
Party may employ separate counsel at the expense of the Indemnifying Party, and
upon written notification thereof, the Indemnifying Party shall not have the
right to assume the defense of such action on behalf of the Indemnified Party;
provided further that the Indemnifying Party shall not, in connection with any
one such action or separate but substantially similar or related actions in the
same jurisdiction arising out of the same general allegations or circumstances,
be liable for the reasonable fees and expenses of more than one separate firm of
attorneys at any time for the Indemnified Party, which firm shall be designated
in writing by the Indemnified Party. Notwithstanding the foregoing, the
Indemnifying Party shall be prohibited from confessing or settling any criminal
allegations brought against the Indemnified Party without the express written
consent of the Indemnified Party.
(c) If the Indemnifying Party fails to notify the Indemnified Party
within the Election Period that the Indemnifying Party elects to defend the
Indemnified Party pursuant to Section 13.3(b), or if the Indemnifying Party
elects to defend the Indemnified Party pursuant to Section 13.3(b) but fails
diligently and promptly to prosecute or settle the Third Party Claim, then the
Indemnified Party shall have the right to defend, at the sole cost and expense
of the Indemnifying Party (if the Indemnified Party is entitled to
indemnification hereunder), the Third Party Claim by all appropriate
proceedings, which proceedings shall be promptly and vigorously prosecuted by
the Indemnified Party to a final conclusion or settled. The Indemnified Party
shall have full control of such defense and proceedings, provided, however, that
the Indemnified Party may not enter into, without the Indemnifying Party's
consent, which shall not be unreasonably withheld, any compromise or settlement
of such Third Party Claim. Notwithstanding the foregoing, if the Indemnifying
Party has delivered a written notice to the Indemnified Party to the effect that
the Indemnifying Party disputes their potential liability to the Indemnified
Party under this Article XIII and if such dispute is resolved in favor of the
Indemnifying Party, the Indemnifying Party shall not be required to bear the
costs and expenses of the Indemnified Party's defense pursuant to this Section
or of the Indemnifying Party's participation therein at the Indemnified Party's
request, and the Indemnified Party shall reimburse the Indemnifying Party in
full for all costs and expenses of
44
<PAGE>
such litigation. The Indemnifying Party may participate in, but not control, any
defense or settlement controlled by the Indemnified Party pursuant to this
Section 13.3(c), and the Indemnifying Party shall bear its own costs and
expenses with respect to such participation; provided, however, that if the
named parties to any such action (including any impleaded parties) include both
the Indemnifying Party and the Indemnified Party, and the Indemnifying Party has
been advised by counsel that there may be one or more legal defenses available
to it that are different from or additional to those available to the
Indemnified Party, then the Indemnifying Party may employ separate counsel and
upon written notification thereof, the Indemnified Party shall not have the
right to assume the defense of such action on behalf of the Indemnifying Party.
(d) In the event any Indemnified Party should have a claim against
any Indemnifying Party hereunder that does not involve a Third Party Claim, the
Indemnified Party shall transmit to the Indemnifying Party a written notice (the
"Indemnity Notice") describing in reasonable detail the nature of the claim, an
estimate of the amount of damages attributable to such claim and the basis of
the Indemnified Party's request for indemnification under this Agreement. If the
Indemnifying Party does not notify the Indemnified Party within 60 days from its
receipt of the Indemnity Notice that the Indemnifying Party disputes such claim,
the claim specified by the Indemnified Party in the Indemnity Notice shall be
deemed a liability of the Indemnifying Party hereunder. If the Indemnifying
Party has timely disputed such claim, as provided above, such dispute shall be
resolved by litigation in an appropriate court of competent jurisdiction if the
parties do not reach a settlement of such dispute within 30 days after notice of
a dispute is given.
(e) Payments of all amounts owing by any Indemnifying Party pursuant
to this Article XIII relating to a Third Party Claim shall be made within 30
days after the latest of (i) the settlement of such Third Party Claim, (ii) the
expiration of the period for appeal of a final adjudication of such Third Party
Claim, or (iii) the expiration of the period for appeal of a final adjudication
of the Indemnifying Party's liability to the Indemnified Party under this
Agreement. Payments of all amounts owing by the Indemnifying Party pursuant to
Section 13.3(d) shall be made within 30 days after the later of (i) the
expiration of the 60-day Indemnity Notice period or (ii) the expiration of the
period for appeal of a final adjudication of the Indemnifying Party's liability
to the Indemnified Party under this Agreement. During the two-year period
following the Effective Time, each Stockholder shall be entitled to satisfy
payments owed to Tatonka by transfer of Tatonka Common Stock from such
Stockholder to Tatonka. For all purposes of this Agreement, the value of each
share of Tatonka Common Stock transferred to Tatonka pursuant to this Agreement
shall be calculated by averaging the daily closing prices (i.e., last sale
price, regular way) for a share of Tatonka Common Stock for the 20 consecutive
trading days on which such shares are actually traded on the NASDAQ National
Market System preceding the date of the Claim Notice or Indemnity Notice, as the
case may be, if the Tatonka Common Stock is so traded at the time. If the
Tatonka Common Stock is not traded on the NASDAQ National Market System at the
time, the average of the high bid and low asked prices as reported in the Wall
Street Journal, or if not so reported, as furnished by a professional market
maker making a market in the Tatonka Common Stock and selected by the Board of
Directors of Tatonka, shall be used. The rights of any
45
<PAGE>
Stockholder to transfer shares of Tatonka Common Stock in satisfaction of
payments owed to Tatonka pursuant to this Agreement shall terminate at the end
of the two-year period following the Effective Time.
(f) The Indemnifying Party shall provide the Indemnified Party with
written notice of any firm offer that is made to settle or compromise a Third
Party Claim against an Indemnified Party. If a firm offer is made to settle such
a claim solely by the payment of money damages and the Indemnifying Party
notifies the Indemnified Party in writing that the Indemnifying Party agrees to
such settlement, but the Indemnified Party elects not to accept and agree to it,
the Indemnified Party may continue to contest or defend such Third Party Claim
and, in such event, the total maximum liability of the Indemnifying Party to
indemnify or otherwise reimburse the Indemnified Party hereunder with respect to
such a claim shall be limited to and shall not exceed the amount of such
settlement offer, plus reasonable out-of-pocket costs and reasonable expenses
(including reasonable attorneys' fees and disbursements) to the date of notice
that the Indemnifying Party desired to accept such settlement.
(g) Notwithstanding anything contained in this Agreement or the
Merger Agreement to the contrary, the Indemnifying Parties in the aggregate (i)
shall have no obligation hereunder to provide indemnification for the first
$50,000 of Damages (without counting Immaterial Claims as defined below), and
(ii) in no event shall the Indemnifying Parties have any liability hereunder
with respect to any singular incident or a fact involving a breach or inaccuracy
of the Company if the Damages from such claim are equal to or less than $7,500
("Immaterial Claims").
Section 13.4. Costs, Expenses and Legal Fees. Whether or not the
transactions contemplated hereby are consummated, each party hereto shall bear
its own costs and expenses (including attorneys' fees), except that each party
hereto agrees to pay the costs and expenses (including reasonable attorneys'
fees and expenses) incurred by the other parties in successfully (a) enforcing
any of the terms of this Agreement or (b) proving that another party breached
any of the terms of this Agreement.
Section 13.5. Tax Benefits; Insurance Proceeds. The total amount of any
indemnity payments owed by one party to another party to this Agreement shall be
reduced by any correlative tax benefit received by the party to be indemnified
or the net proceeds received by the party to be indemnified with respect to
recovery from third parties or insurance proceeds, and such correlative
insurance benefit shall be net of the insurance premium, if any, that becomes
due as a result of such claim.
Section 13.6. Dispute Resolution.
(a) Arbitration. The parties hereto agree that any claim,
controversy, dispute or disagreement between or among any of the parties arising
out of or relating to this Agreement shall be governed exclusively by the terms
and provisions of this Section 13.6; provided, however, that within ten days
from the date which any claim, controversy, dispute or disagreement cannot be
resolved and prior to commencing an arbitration procedure pursuant to this
Section 13.6, the parties shall meet to discuss and consider other alternative
dispute resolution procedures other than arbitration including, but not limited
to, mediation. If at any
46
<PAGE>
time prior to the rendering of the decision by the arbitrator (or pursuant to
such other alternative dispute resolution procedure) as contemplated in this
Section 13.6 to the extent a party makes a written offer to the other party
proposing a settlement of the matter(s) at issue and such offer is rejected,
then the party rejecting such offer shall be obligated to pay the costs and
expenses (excluding the amount of the award granted under the decision) of the
party that offered the settlement from the date such offer was received by such
other party if the decision is for a dollar amount that is less than the amount
of such offer to settle. Notwithstanding the foregoing, the terms and provisions
of this Section 13.6 shall not preclude any party hereto from seeking, or a
court of competent jurisdiction from granting, a temporary restraining order,
temporary injunction or other equitable relief for any breach of (i) any
non-competition or confidentiality covenant or (ii) any duty, obligation,
covenant, representation or warranty, the breach of which may cause irreparable
harm or damage.
(b) Arbitrators. In the event there is a claim, controversy, dispute
or disagreement among the parties hereto arising out of or relating to this
Agreement (including any claim based on or arising from an alleged tort) and the
parties hereto have not reached agreement regarding an alternative to
arbitration, the parties agree to select within 30 days of notice by a party to
the other of its desire to seek arbitration under this Section 13.6 one
arbitrator mutually acceptable to Tatonka and the Sellers to hear and decide all
such claims under this Section 13.6. Each of the arbitrators proposed shall be
impartial and independent of all parties. If the parties cannot agree on the
selection of an arbitrator within said 30-day period, then any party may in
writing request the judge of the United States District Court for the Northern
District of Texas senior in term of service to appoint the arbitrator and,
subject to this Section 13.6, such arbitrator shall hear all arbitration matters
arising under this Section 13.6.
(c) Applicable Rules.
(1) Each arbitration hearing shall be held at a place in Dallas,
Texas acceptable to the arbitrator. The arbitration shall be conducted in
accordance with the Commercial Arbitration Rules of the American
Arbitration Association to the extent such rules do not conflict with the
terms hereof; provided, however, that if the parties hereto agree to an
alternative to arbitration they may agree to an alternative set of rules,
including as to rules of evidence and procedure. The decision of the
arbitrator shall be reduced to writing and shall be binding on the parties
and such decision shall contain a concise statement of the reasons in
support of such decision. Judgment upon the award(s) rendered by the
arbitrator may be entered and execution had in any court of competent
jurisdiction or application may be made to such court for a judicial
acceptance of the award and an order of enforcement. The charges and
expenses of the arbitrator shall be shared equally by the parties to the
hearing.
(2) The arbitration shall commence within ten days after the
arbitrator is selected in accordance with the provisions of this Section
13.6. In fulfilling his duties with respect to determining the amount of
any loss, the arbitrator may consider such matters as, in the opinion of
the arbitrator, are necessary or helpful to make a proper valuation. The
arbitrator may consult with and engage disinterested third parties to
advise the arbitrator.
47
<PAGE>
The arbitrator shall not add any interest factor reflecting the time value
of money to the amount of any loss and shall not award any punitive
damages.
(3) If the arbitrator selected hereunder should die, resign or be
unable to perform his or her duties hereunder, the parties, or such senior
judge (or such judge's successor) in the event the parties cannot agree,
shall select a replacement arbitrator. The procedure set forth in this
Section 13.6 for selecting the arbitrator shall be followed from time to
time as necessary.
(4) As to any determination of the amount of any loss, or as to the
resolution of any other claim, controversy, dispute or disagreement, that
under the terms hereof is made subject to arbitration, no lawsuit based on
such claimed loss or such resolution shall be instituted by the parties
hereto, other than to compel arbitration proceedings or enforce the award
of the arbitrator, except as otherwise provided in Section 11.7(b).
(5) All privileges under Texas and Federal law, including
attorney-client and work- product privileges, shall be preserved and
protected to the same extent that such privileges would be protected in a
Federal court proceeding applying Texas law.
ARTICLE XIV
TERMINATION
Section 14.1. Termination. This Agreement may be terminated and the Merger
and the Acquisitions may be abandoned:
(a) at any time prior to the Effective Time by mutual agreement of
all parties;
(b) at any time prior to the Effective Time by Tatonka if any
material representation or warranty of the Company or any Stockholder contained
in this Agreement or in any certificate or other document executed and delivered
by the Company or any Stockholder pursuant to this Agreement is or becomes
untrue or breached in any material respect or if the Company or any Stockholder
fails to comply in any material respect with any material covenant or agreement
contained in this Agreement, and any such misrepresentation, noncompliance or
breach is not cured, waived or eliminated within 30 days after receipt of
written notice thereof;
(c) at any time prior to the Effective Time by the Company if any
representation or warranty of Tatonka or Tatonka Sub contained in this Agreement
or in any certificate or other document executed and delivered by Tatonka or
Tatonka Sub pursuant to this Agreement is or becomes untrue in any material
respect of if Tatonka fails to comply in any material respect with any covenant
or agreement contained in this Agreement, and any such misrepresentation,
noncompliance or breach is not cured, waived or eliminated within 30 days after
receipt of written notice thereof;
(d) at any time prior to the Effective Time by Tatonka if, as a
result of the conduct of due diligence and regulatory compliance procedures,
Tatonka deems termination to be advisable; or
48
<PAGE>
(e) by Tatonka or the Company if the Merger shall not have been
consummated by March 31, 1998.
Section 14.2. Effect of Termination. Except as set forth in Section 15.3,
in the event this Agreement is terminated pursuant to this Article XIV, this
Agreement shall forthwith become void.
ARTICLE XV
NONDISCLOSURE OF CONFIDENTIAL INFORMATION
Section 15.1. Non-Disclosure Covenant. The Company recognizes and
acknowledges that each has in the past, currently has, and in the future may
possibly have, access to certain Confidential Information of Tatonka and the
Surviving Corporation that is valuable, special and a unique asset of such
entity's business. Tatonka and Tatonka Sub acknowledges that they have had in
the past, currently have, and in the future may possibly have, access to certain
Confidential Information of the Company that is valuable, special and a unique
asset of each such business. The Company, Tatonka and Tatonka Sub, severally,
agree that they will not disclose such Confidential Information to any person,
firm, corporation, association or other entity for any purpose or reason
whatsoever, except (a) to authorized representatives of Tatonka, Tatonka Sub,
Surviving Corporation and the Company and (b) to counsel and other advisers to
Tatonka, Tatonka Sub, Surviving Corporation and the Company provided that such
advisers (other than counsel) agree to the confidentiality provisions of this
Section 15.1, unless (i) such information becomes available to or known by the
public generally through no fault of the Company, Tatonka or Tatonka Sub, as the
case may be, (ii) disclosure is required by law or the order of any governmental
authority under color of law, provided, that prior to disclosing any information
pursuant to this clause (ii) the Company, Tatonka or Tatonka Sub, as the case
may be, shall, if possible, give prior written notice thereof to the Company,
Tatonka or Tatonka Sub and provide the Company, Tatonka or Tatonka Sub with the
opportunity to contest such disclosure, (iii) the disclosing party reasonably
believes that such disclosure is required in connection with the defense of a
lawsuit against the disclosing party, or (iv) the disclosing party is the sole
and exclusive owner of such Confidential Information as a result of the Merger
or otherwise. In the event of a breach or threatened breach by the Company, on
the one hand, and Tatonka or Tatonka Sub, on the other hand, of the provisions
of this Section, Tatonka, Tatonka Sub, the Surviving Corporation and the Company
shall be entitled to an injunction restraining the other party, as the case may
be, from disclosing, in whole or in part, such Confidential Information. Nothing
in this Agreement shall be construed as prohibiting any of such parties from
pursuing any other available remedy for such breach or threatened breach,
including the recovery of damages.
Section 15.2. Damages. Because of the difficulty of measuring economic
losses as a result of the breach of the foregoing covenants, and because of the
immediate and irreparable damage that would be caused for which they would have
no other adequate remedy, Tatonka, Tatonka Sub, the Surviving Corporation and
the Company agree that, in the event of a breach by either of them of the
foregoing covenant, the covenant may be
49
<PAGE>
enforced against them by injunctions and restraining orders.
Section 15.3. Survival. The obligations of the parties under this Article
XV shall survive the termination of this Agreement.
ARTICLE XVI
MISCELLANEOUS
Section 16.1. Amendment; Waivers. This Agreement may be amended, modified
or supplemented only by an instrument in writing executed by all the parties
hereto. Any waiver of any terms and conditions hereof must be in writing, and
signed by the parties hereto. The waiver of any of the terms and conditions of
this Agreement shall not be construed as a waiver of any other terms and
conditions hereof.
Section 16.2. Assignment. Neither this Agreement nor any right created
hereby or in any agreement entered into in connection with the transactions
contemplated hereby shall be assignable by any party hereto, except by Tatonka
to a wholly owned subsidiary of Tatonka; provided that any such assignment shall
not relieve Tatonka of its obligations hereunder.
Section 16.3. Parties in Interest; No Third Party Beneficiaries. Except as
otherwise provided in this Agreement, the terms and conditions of this Agreement
shall inure to the benefit of and be binding upon the respective heirs, legal
representatives, successors and assigns of the parties hereto. Tatonka and
Tatonka Sub acknowledge and agree that the rights and remedies of the Company
under this Agreement will be directly available to the Stockholders as third
party beneficiaries of the rights and remedies of the Company under this
Agreement, including, without limitation, the rights and remedies under Article
XIII to indemnification from Tatonka and Tatonka Sub against Damages incurred by
the Stockholders resulting from a breach by Tatonka or Tatonka Sub of any
representation, warranty or covenant of Tatonka or Tatonka Sub contained in this
Agreement. Except as provided in the preceding sentence or as otherwise provided
in this Agreement, neither this Agreement nor any other agreement contemplated
hereby shall be deemed to confer upon any person not a party hereto or thereto
any rights or remedies hereunder or thereunder.
Section 16.4. Entire Agreement. This Agreement and the agreements
contemplated hereby constitute the entire agreement of the parties regarding the
subject matter hereof, and supersede all prior agreements and understandings,
both written and oral, among the parties, or any of them, with respect to the
subject matter hereof.
Section 16.5. Severability. If any provision of this Agreement is held to
be illegal, invalid or unenforceable under present or future laws effective
during the term hereof, such provision shall be fully severable and this
Agreement shall be construed and enforced as if such illegal, invalid or
unenforceable provision never comprised a part hereof; and the remaining
provisions hereof shall remain in full force and effect and shall not be
affected by the illegal, invalid or unenforceable provision or by its severance
therefrom. Furthermore, in lieu of such illegal, invalid or unenforceable
provision, there shall be added automatically as part of this Agreement a
provision as similar in its terms to such illegal, invalid or
50
<PAGE>
unenforceable provision as may be possible and be legal, valid and enforceable.
Section 16.6. Survival of Representations, Warranties and Covenants. The
representations, warranties and covenants contained in this Agreement shall
survive the Closing and all statements contained in any certificate, exhibit or
other instrument delivered by or on behalf of the Company, any Stockholder,
Tatonka or Tatonka Sub pursuant to this Agreement shall be deemed to have been
representations and warranties by the Company, such Stockholder, Tatonka and
Tatonka Sub. Notwithstanding any provision in this Agreement to the contrary,
the representations and warranties contained in this Agreement shall survive the
Closing until the second anniversary of the Closing Date except that (a) the
representations and warranties set forth in Section 3.20 with respect to
environmental matters shall survive for a period of ten years, (b) the
representations and warranties set forth in Section 3.28 with respect to tax
matters shall survive until such time as the limitations period has run for all
tax periods ended prior to the Closing Date, (c) the representations and
warranties contained in Section 3.25 and Section 3.31 with respect to healthcare
matters shall survive for a period of six years and (d) solely for purposes of
Section 13.1(c) and Section 13.2(c), and solely to the extent that any party to
be indemnified pursuant to such provisions actually incurs liability under the
Securities Act, the Exchange Act or any other Federal or state securities law,
the representations and warranties set forth therein shall survive until the
expiration of any applicable limitations period.
Section 16.7. Governing Law. THIS AGREEMENT AND THE RIGHTS AND OBLIGATIONS
OF THE PARTIES HERETO SHALL BE GOVERNED BY AND CONSTRUED AND ENFORCED IN
ACCORDANCE WITH THE SUBSTANTIVE LAWS (BUT NOT THE RULES GOVERNING CONFLICTS OF
LAWS) OF THE STATE OF OKLAHOMA.
Section 16.8. Captions. The captions in this Agreement are for convenience
of reference only and shall not limit or otherwise affect any of the terms or
provisions hereof.
Section 16.9. Gender and Number. When the context requires, the gender of
all words used in this Agreement shall include the masculine, feminine and
neuter and the number of all words shall include the singular and plural.
Section 16.10. Confidentiality; Publicity and Disclosures. Each party shall
keep this Agreement and its terms confidential, and shall make no press release
or public disclosure, either written or oral, regarding the transactions
contemplated by this Agreement without the prior knowledge and consent of the
other parties hereto; provided that the foregoing shall not prohibit any
disclosure (a) by press release, filing or otherwise that Tatonka has determined
in its good faith judgment and after advice of legal counsel to be required by
Federal securities laws or the rules of the National Association of Securities
Dealers, (b) to attorneys, accountants, investment bankers or other agents of
the parties assisting the parties in connection with the transactions
contemplated by this Agreement and (c) by Tatonka in connection with conducting
an examination of the operations and assets of the Companies; provided that
Tatonka shall reasonably promptly provide notice of any release. In the event
that the transactions contemplated hereby are not consummated for any reason
whatsoever,
51
<PAGE>
the parties hereto agree not to disclose or use any Confidential Information
they may have concerning the affairs of the other parties, except for
information that is required by law to be disclosed; provided that should the
transactions contemplated hereby not be consummated, nothing contained in this
Section shall be construed to prohibit the parties hereto from operating
businesses in competition with each other.
Section 16.11. Notice. Whenever this Agreement requires or permits any
notice, request, or demand from one party to another, the notice, request or
demand must be in writing to be effective and shall be deemed to be delivered
and received (i) if personally delivered or if delivered by telex, telegram or
courier service, when delivered to the party to whom notice is sent, (ii) if
delivered by facsimile transmission, when so sent and receipt acknowledged by
receipt or (iii) if delivered by mail (whether actually received or not), at the
close of business on the third business day next following the day when placed
in the mail, postage prepaid, certified or registered, addressed to the
appropriate party or parties, at the address of such party set forth below (or
at such other address as such party may designate by written notice to all other
parties in accordance herewith):
If to Tatonka or Tatonka Sub:
Tatonka Energy, Inc.
1601 N.W. Expressway, Suite 1910
Oklahoma City, Oklahoma 73118
Attn. Mr. Joe R. Love
with a copy to:
Derrick & Briggs
Bank One Center, 20th Floor
100 N. Broadway Ave.
Oklahoma City, Oklahoma 73102
Attn. Mr. Gary W. Derrick
If to the Company or any Stockholder:
Phy. Med., Inc.
9603 White Rock Trail, Suite 100
Dallas, Texas 75258
Attn. Mr. George C. Barker
with a copy to:
Bruce B. Hart, Esq.
Bruce B. Hart, P.C.
10440 North Central Expressway
Suite 610
Dallas Texas 75231
AND
52
<PAGE>
James V. Grevelle, Esq.
James V. Grevelle, P.C.
15303 Dallas Parkway, Suite 700, LB 17 Dallas, Texas 75248
Section 16.12. No Waiver; Remedies. No party hereto shall by any act
(except by written instrument pursuant to Section 16.1 hereof), delay,
indulgence, omission or otherwise be deemed to have waived any right or remedy
hereunder or to have acquiesced in any default in or breach of any of the terms
and conditions hereof. No failure to exercise, nor any delay in exercising, on
the part of any party hereto, any right, power or privilege hereunder shall
operate as a waiver thereof. No single or partial exercise of any right, power
or privilege hereunder shall preclude any other or further exercise thereof or
the exercise of any other right, power or privilege. No remedy set forth in this
Agreement or otherwise conferred upon or reserved to any party shall be
considered exclusive of any other remedy available to any party, but the same
shall be distinct, separate and cumulative and may be exercised from time to
time as often as occasion may arise or as may be deemed expedient.
Section 16.13. Counterparts. This Agreement may be executed in multiple
counterparts, each of which shall be deemed an original, and all of which
together shall constitute one and the same instrument.
Section 16.14. Defined Terms. Terms used in the Exhibits to this Agreement
and the Disclosure Schedules with their initial letter capitalized and not
otherwise defined therein shall have the meanings as assigned to such terms in
this Agreement.
53
<PAGE>
IN WITNESS WHEREOF, the parties have duly executed this Agreement as of the
date first written above.
TATONKA: TATONKA ENERGY, INC.
By: /s/ Joe Foor
------------------------------
Joe Foor
President
TATONKA SUB: TATONKA ENERGY SUBSIDIARY, INC.,
By: /s/ Joe Foor
-------------------------------
Joe Foor
President
THE COMPANY: PHY. MED., INC.
By: /s/ George C. Barker
-------------------------------
George C. Barker
President
BARKER:
/s/ George C. Barker
-------------------------------
George C. Barker
ESOP: EMPLOYEE STOCK OWNERSHIP
PLAN OF PHY. MED, INC.
By: /s/ George C. Barker
------------------------------
George C. Barker, Trustee
54
<PAGE>
Exhibit A - Merger Consideration
The Stockholders shall receive the following Tatonka Common Stock as their
Merger Consideration:
George C. Barker...............................................54,230,788 shares
The ESOP.......................................................15,184,621 shares
Total Merger Consideration.....................................69,415,409 shares
55
<PAGE>
<TABLE>
<CAPTION>
Exhibit "B" - Preferred Stock Listing
CANCELLED/
CERTIFICATE PREFERRED DATE CONVERTED COMMON REMAINING
SHAREHOLDER CO. NO. SHARES CONVERTED SHARES SHARES PREFERRED
- ----------- --- --------- --------- --------- ---------- ------- ---------
<S> <C> <C> <C> <C>
Adams, Gaylon SEC P-2- 1 4,098 4,098
Adams, John SEC P-2- 2 2,089 2,089
B-SH Enterprises SEC P-2- 11 3,688 3,688
Beals, James A. & Teri SEC P-2- 5 2,048 2,048
Bernstein, Barbara L. SEC P-2- 34 4,098 4,098
Bird Investment SEC P-2- 6 2,048 2,048
Blanton, Mary C. SEC P-2- 8 2,048 4/95 (2,048) 0
Blanton, Mary C. 1991 Revocable TEI P- 12 2,048 2,048
Trust U/A Dtd.
Boatman, Dr. Karl K. SEC P-2- 7 4,098 4,098
Bowman, Roger B. SEC P-2- 9 2,048 1/95 (2,048) 0
Bowman, Roger B. Revocable TEI P- 1 2,048 2,048
Living Trust
Brelsford, C.D. & Barbara SEC P-2- 10 2,048 1/95 (2,048) 0
Buchanan, James C. III SEC P-2- 12 2,048 2,048
Buchholz, Don SEC P-2- 13 2,048 2,048
Cobb, Allen B. SEC P-2- 14 2,048 1/95 (2,048) 0
Cobb, Allen B. TEI P- 2 2,048 2,048
Croley, Marion, D.D.S. SEC P-2- 15 2,048 1/95 (2,048) 0
Davis, William A. SEC P-2- 16 4,098 4,098
Diamond H. Partnership SEC P-2- 18 8,195 8,195
Evans, Mary J. SEC P-2- 19 2,459 3/95 (2,459) 0
Evans, Mary J. TEI P- 9 2,459 2,459
Foor, Joe Paul SEC P-2 4 8,112 3/95 (8,112) 27,413 0
Foor, Anne C. TEI P- 11 4,000 4,000
Foor, Joe Paul TEI P- 10 4,112 4/95 (4,112) 27,413 0
Garland, Bud F., Trustee SEC P-2- 20 2,048 9/93 (2,048) 13,653 0
Garland, Gary F. SEC P-2- 21 2,048 2,048
Graves, Ron L. SEC P-2- 22 2,048 4/95 (2,048) 0
Graves, Ron L. TEI P- 13 2,048 2,048
HiPoint Petroleum SEC P-2- 23 12,290 12,290
Holt, A.B. SEC P-2- 24 2,048 2,048
56
<PAGE>
Hutchison, Harold D. SEC P-2- 25 2,048 3/95 (2,048) 0
Hutchison, Harold D. TEI P- 8 2,048 2,048
James, Mel SEC P-2- 3 2,089 (2,089) 0
Johnston, John W. SEC P-2- 26 4,098 4,098
Kemper Clearing Corp. TEI P- 7 2,048 4/96 (2,048) 0
EVEREN Clearing Corp. TEI P- 14 2,048 2,048
Kendrick, Carl B. SEC P-2- 27 2,048 (2,048) 0
McGarrahan, Dedmon II SEC P-2- 17 2,048 2,048
Mitchell, Robert H. SEC P-2- 27 2,048 2,048
Partridge Capital Corporation SEC P-2- 29 10,242 10,242
Payne, Vivian S. SEC P-2- 30 2,048 1/95 (2,048) 0
Payne, Vivian S. TEI P- 3 2,048 2,048
Prudential Securities Incorporated TEI P- 4 2,048 2,048
R & M Investments SEC P-2- 31 2,048 2,048
Ritchey, J. Rickey & Jack Reynolds, SEC P-2- 32 2,048 2,048
Rosenthal, Dr. Avram E. SEC P-2- 33 4,098 1/95 (4,098) 0
Rosenthal, Dr. Avram E. TEI P- 5 4,098 4,098
Scholl, Richard L. SEC P-2- 35 2,048 (2,048) 0
Seikel Energy Partnership SEC P-2- 36 12,290 12,290
Spivey, Dan, M.D. SEC P-2- 37 2,048 2,048
Temple & Temple SEC P-2- 38 2,048 2,048
Thompson, James L. & Steve SEC P-2- 39 6,146 6,146
Horowitz
Triplett-Organ SEC P-2- 40 2,048 1/95 (2,048) 0
Triplett-Organ TEI P- 6 2,048 2,048
Upp, Brian H. SEC P-2- 41 2,048 2,048
Vucicevic, Dusan, M.D. SEC P-2- 43 2,048 2,048
Wood, C. Courtney SEC P-2- 42 2,048 2,048
------- ---------------------------------------
182,633 (47,494) 68,479 135,139
======= =======================================
</TABLE>
57
<PAGE>
Exhibit C - Stockholder Representation Letter
To the Board of Directors of Tatonka:
As a Stockholder and party to the Merger Agreement of even date herewith,
and in consideration of the shares of Tatonka Common Stock that I will receive
if the Merger is closed, I hereby represent to you as follows:
(a) I am acquiring the Tatonka Common Stock for my own account for
investment and not with a view to, or for resale in connection with,
any distribution or the grant of any participation in the Tatonka
Common Stock, and I have has no present intention of distributing any
Tatonka Common Stock. I am an "accredited investor" as that term is
defined in Regulation D under the Securities Act of 1993 (the "Act"). I
understand that the shares of Tatonka Common Stock that I am to receive
as the Merger Consideration are "restricted securities" under the Act
and can only be sold under Rule 144 as promulgated under the Act.
(b) I represent and warrant that I am qualified by my own experience in
financial and business matters to evaluate the Merger and that I am
able to bear any economic loss resulting from the Merger and to hold
such Tatonka Common Stock indefinitely. I understand that no Federal or
state governmental authority has made any finding or determination
relating the fairness of the Merger. I represent and warrant that the
Merger is suitable for me in light of the circumstances.
(c) I am familiar with the business, operations and financial condition of
Phy.Med., Inc. and have had full and complete access to all material
information about Tatonka and such other information I deem material to
the business of Tatonka and Phy.Med. Inc., and to the consummation of
the Merger, and I am relying upon no oral representations in connection
with the Merger.
These representations and warranties are made as of the Closing Date.
Capitalized terms used herein shall have the meaning given in the Merger
Agreement.
Sincerely,
/s/ George C. Barker
--------------------
George C. Barker
1
<PAGE>
To the Board of Directors of Tatonka:
As a Stockholder and party to the Merger Agreement of even date herewith,
and in consideration of the shares of Tatonka Common Stock that it will receive
if the Merger is closed, the Employee Stock Ownership Plan of Phy. Med., Inc.
(the "ESOP") hereby represents to you as follows:
(a) The ESOP is acquiring the Tatonka Common Stock for its own account for
investment and not with a view to, or for resale in connection with,
any distribution or the grant of any participation in the Tatonka
Common Stock, and it has no present intention of distributing any
Tatonka Common Stock. It is "accredited investor" as that term is
defined in Regulation D under the Securities Act of 1993 (the "Act").
The ESOP understands that the shares of Tatonka Common Stock that it is
to receive as the Merger Consideration are "restricted securities"
under the Act and can only be sold under Rule 144 as promulgated under
the Act.
(b) The Trustee of the ESOP represents and warrants that he is qualified by
his own experience in financial and business matters to evaluate the
Merger and that the Merger and the investment in the Tatonka Common
Stock is a suitable investment for the ESOP. The ESOP is able to bear
any economic loss resulting from the Merger and to hold such Tatonka
Common Stock indefinitely. The ESOP acknowledges that no Federal or
state governmental authority has made any finding or determination
relating the fairness of the Merger.
(c) The ESOP has had full and complete access to all material information
about Tatonka and such other information its Trustee deems material to
the business of Tatonka and Phy.Med. Inc., and to the consummation of
the Merger. The ESOP is relying upon no oral representations in
connection with the Merger.
These representations and warranties are made as of the Closing Date.
Capitalized terms used herein shall have the meaning given in the Merger
Agreement.
Sincerely,
Employee Stock Ownership Plan of Phy. Med., Inc.
By: /s/ George C. Barker, Trustee
-----------------------------
George C. Barker, Trustee
2
